<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39326415</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>04</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>07</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-4172</ISSN><JournalIssue CitedMedium="Internet"><Volume>187</Volume><Issue>20</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>03</Day></PubDate></JournalIssue><Title>Cell</Title><ISOAbbreviation>Cell</ISOAbbreviation></Journal><ArticleTitle>Mechanisms of long COVID and the path toward therapeutics.</ArticleTitle><Pagination><StartPage>5500</StartPage><EndPage>5529</EndPage><MedlinePgn>5500-5529</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.cell.2024.07.054</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0092-8674(24)00886-9</ELocationID><Abstract><AbstractText>Long COVID, a type of post-acute sequelae of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (PASC) defined by medically unexplained symptoms following infection with SARS-CoV-2, is a newly recognized infection-associated chronic condition that causes disability in some people. Substantial progress has been made in defining its epidemiology, biology, and pathophysiology. However, there is no cure for the tens of millions of people believed to be experiencing long COVID, and industry engagement in developing therapeutics has been limited. Here, we review the current state of knowledge regarding the biology and pathophysiology of long COVID, focusing on how the proposed mechanisms explain the physiology of the syndrome and how they provide a rationale for the implementation of a broad experimental medicine and clinical trials agenda. Progress toward preventing and curing long COVID and other infection-associated chronic conditions will require deep and sustained investment by funders and industry.</AbstractText><CopyrightInformation>Copyright &#xa9; 2024 The Authors. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Peluso</LastName><ForeName>Michael J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Division of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, San Francisco, CA, USA. Electronic address: michael.peluso@ucsf.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deeks</LastName><ForeName>Steven G</ForeName><Initials>SG</Initials><AffiliationInfo><Affiliation>Division of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, San Francisco, CA, USA. Electronic address: steven.deeks@ucsf.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K23 AI157875</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS136197</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cell</MedlineTA><NlmUniqueID>0413066</NlmUniqueID><ISSNLinking>0092-8674</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="Y">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000093485" MajorTopicYN="N">COVID-19 Drug Treatment</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">long COVID</Keyword><Keyword MajorTopicYN="N">post-COVID-19 condition</Keyword><Keyword MajorTopicYN="N">post-acute COVID-19 syndrome</Keyword><Keyword MajorTopicYN="N">post-acute sequelae of SARS-CoV-2 infection</Keyword></KeywordList><CoiStatement>Declaration of interests M.J.P. has received consulting fees from Gilead Sciences, AstraZeneca, BioVie, Apellis Pharmaceuticals, and BioNTech and research support from Aerium Therapeutics and Shionogi outside the submitted work. S.G.D. reports consulting for Enanta Pharmaceuticals, BioVie, and Pfizer and reports research support from Aerium Therapeutics outside the submitted work.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>10</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>7</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>7</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>10</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>6</Day><Hour>4</Hour><Minute>17</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>27</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>26</Day><Hour>18</Hour><Minute>41</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39326415</ArticleId><ArticleId IdType="mid">NIHMS2025755</ArticleId><ArticleId IdType="pmc">PMC11455603</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2024.07.054</ArticleId><ArticleId IdType="pii">S0092-8674(24)00886-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Nalbandian A et al. Post-acute COVID-19 syndrome. Nat. Med (2021). 10.1038/s41591-021-01283-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01283-z</ArticleId><ArticleId IdType="pmc">PMC8893149</ArticleId><ArticleId IdType="pubmed">33753937</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Aly Z, Xie Y &amp; Bowe B High-dimensional characterization of post-acute sequelae of COVID-19 Nature 594, 259&#x2013;264 (2021). 10.1038/s41586-021-03553-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03553-9</ArticleId><ArticleId IdType="pubmed">33887749</ArticleId></ArticleIdList></Reference><Reference><Citation>Global Burden of Disease Long, C. C. et al. Estimated Global Proportions of Individuals With Persistent Fatigue, Cognitive, and Respiratory Symptom Clusters Following Symptomatic COVID-19 in 2020 and 2021. JAMA 328, 1604&#x2013;1615 (2022). 10.1001/jama.2022.18931</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2022.18931</ArticleId><ArticleId IdType="pmc">PMC9552043</ArticleId><ArticleId IdType="pubmed">36215063</ArticleId></ArticleIdList></Reference><Reference><Citation>Organization, W. H. &amp; Others. A clinical case definition of post COVID-19 condition by a Delphi consensus, 6 October 2021. (World Health Organization, 2021).</Citation></Reference><Reference><Citation>Hhs. COVID.gov/longcovid - Virus that causes COVID-19 can experience long-term effects from their infection.</Citation></Reference><Reference><Citation>Thaweethai T et al. Development of a Definition of Postacute Sequelae of SARS-CoV-2 Infection. JAMA 329, 1934&#x2013;1946 (2023). 10.1001/jama.2023.8823</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2023.8823</ArticleId><ArticleId IdType="pmc">PMC10214179</ArticleId><ArticleId IdType="pubmed">37278994</ArticleId></ArticleIdList></Reference><Reference><Citation>Venkatesan P NICE guideline on long COVID. Lancet Respir Med 9, 129 (2021). 10.1016/S2213-2600(21)00031-X</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(21)00031-X</ArticleId><ArticleId IdType="pmc">PMC7832375</ArticleId><ArticleId IdType="pubmed">33453162</ArticleId></ArticleIdList></Reference><Reference><Citation>Torres M et al. Consensus on post COVID in the Spanish national health system: Results of the CIBERPOSTCOVID eDelphi study. Journal of Infection and Public Health 16, 1784&#x2013;1792 (2023). https://doi.org/10.1016/j.jiph.2023.08.022</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jiph.2023.08.022</ArticleId><ArticleId IdType="pubmed">37741013</ArticleId></ArticleIdList></Reference><Reference><Citation>Koczulla AR et al. [S1 Guideline Post-COVID/Long-COVID]. Pneumologie 75, 869&#x2013;900 (2021). 10.1055/a-1551-9734</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/a-1551-9734</ArticleId><ArticleId IdType="pubmed">34474488</ArticleId></ArticleIdList></Reference><Reference><Citation>Giuliano M et al. Italian good practice recommendations on management of persons with Long-COVID. Front Public Health 11, 1122141 (2023). 10.3389/fpubh.2023.1122141</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fpubh.2023.1122141</ArticleId><ArticleId IdType="pmc">PMC10157646</ArticleId><ArticleId IdType="pubmed">37151592</ArticleId></ArticleIdList></Reference><Reference><Citation>Sick and tired: Casting a long shadow. REPORT - April 2023. Parliament of Australia. Available at: https://www.aph.gov.au/Parliamentary_Business/Committees/House/Health_Aged_Care_and_Sport/LongandrepeatedCOVID/Report.</Citation></Reference><Reference><Citation>LONG COVID. South African National Institute for Communicable Diseases. Available at: https://www.nicd.ac.za/diseases-a-z-index/disease-index-covid-19/long-covid/.</Citation></Reference><Reference><Citation>Ledford H Long COVID is a double curse in low-income nations - here&#x2019;s why. Nature 625, 20&#x2013;22 (2024). 10.1038/d41586-023-04088-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/d41586-023-04088-x</ArticleId><ArticleId IdType="pubmed">38172361</ArticleId></ArticleIdList></Reference><Reference><Citation>Callard F &amp; Perego E How and why patients made Long Covid. Soc. Sci. Med 268, 113426 (2021). 10.1016/j.socscimed.2020.113426</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.socscimed.2020.113426</ArticleId><ArticleId IdType="pmc">PMC7539940</ArticleId><ArticleId IdType="pubmed">33199035</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis HE et al. Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. EClinicalMedicine 38, 101019 (2021). 10.1016/j.eclinm.2021.101019</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2021.101019</ArticleId><ArticleId IdType="pmc">PMC8280690</ArticleId><ArticleId IdType="pubmed">34308300</ArticleId></ArticleIdList></Reference><Reference><Citation>National Academies of Sciences, E. &amp; Medicine. A Long COVID Definition: A Chronic, Systemic Disease State with Profound Consequences. (The National Academies Press, 2024).</Citation><ArticleIdList><ArticleId IdType="pubmed">39110819</ArticleId></ArticleIdList></Reference><Reference><Citation>McCorkell L &amp; Peluso MJ Long COVID research risks losing momentum - we need a moonshot. Nature 622, 457&#x2013;460 (2023). 10.1038/d41586-023-03225-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/d41586-023-03225-w</ArticleId><ArticleId IdType="pubmed">37853144</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis HE, McCorkell L, Vogel JM &amp; Topol EJ Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol 21, 133&#x2013;146 (2023). 10.1038/s41579-022-00846-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-022-00846-2</ArticleId><ArticleId IdType="pmc">PMC9839201</ArticleId><ArticleId IdType="pubmed">36639608</ArticleId></ArticleIdList></Reference><Reference><Citation>Altmann DM, Whettlock EM, Liu S, Arachchillage DJ &amp; Boyton RJ The immunology of long COVID. Nat Rev Immunol 23, 618&#x2013;634 (2023). 10.1038/s41577-023-00904-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-023-00904-7</ArticleId><ArticleId IdType="pubmed">37433988</ArticleId></ArticleIdList></Reference><Reference><Citation>Sherif ZA, Gomez CR, Connors TJ, Henrich TJ &amp; Reeves WB Pathogenic mechanisms of post-acute sequelae of SARS-CoV-2 infection (PASC). Elife 12 (2023). 10.7554/eLife.86002</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.86002</ArticleId><ArticleId IdType="pmc">PMC10032659</ArticleId><ArticleId IdType="pubmed">36947108</ArticleId></ArticleIdList></Reference><Reference><Citation>Proal AD et al. SARS-CoV-2 reservoir in post-acute sequelae of COVID-19 (PASC). Nat Immunol 24, 1616&#x2013;1627 (2023). 10.1038/s41590-023-01601-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-023-01601-2</ArticleId><ArticleId IdType="pubmed">37667052</ArticleId></ArticleIdList></Reference><Reference><Citation>Taquet M et al. Incidence, co-occurrence, and evolution of long-COVID features: A 6-month retrospective cohort study of 273,618 survivors of COVID-19. PLoS Med. 18, e1003773 (2021). 10.1371/journal.pmed.1003773</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.1003773</ArticleId><ArticleId IdType="pmc">PMC8478214</ArticleId><ArticleId IdType="pubmed">34582441</ArticleId></ArticleIdList></Reference><Reference><Citation>Montoy JCC et al. Prevalence of Symptoms &#x2264;12 Months After Acute Illness, by COVID-19 Testing Status Among Adults - United States, December 2020-March 2023. MMWR Morb. Mortal. Wkly. Rep 72, 859&#x2013;865 (2023). 10.15585/mmwr.mm7232a2</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7232a2</ArticleId><ArticleId IdType="pmc">PMC10415002</ArticleId><ArticleId IdType="pubmed">37561663</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie Y, Choi T &amp; Al-Aly Z Long-term outcomes following hospital admission for COVID-19 versus seasonal influenza: a cohort study. The Lancet Infectious Diseases 24, 239&#x2013;255 (2024). 10.1016/S1473-3099(23)00684-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(23)00684-9</ArticleId><ArticleId IdType="pubmed">38104583</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoeg TB, Ladhani S &amp; Prasad V How methodological pitfalls have created widespread misunderstanding about long COVID. BMJ Evid Based Med (2023). 10.1136/bmjebm-2023-112338</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjebm-2023-112338</ArticleId><ArticleId IdType="pmc">PMC11137465</ArticleId><ArticleId IdType="pubmed">37748921</ArticleId></ArticleIdList></Reference><Reference><Citation>Robertson MM et al. The Epidemiology of Long Coronavirus Disease in US Adults. Clin. Infect. Dis 76, 1636&#x2013;1645 (2023). 10.1093/cid/ciac961</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciac961</ArticleId><ArticleId IdType="pubmed">36542514</ArticleId></ArticleIdList></Reference><Reference><Citation>Long COVID. Household Pulse Survey. National Center for Health Statistics. Available at: https://www.cdc.gov/nchs/covid19/pulse/long-covid.htm. (2023).</Citation></Reference><Reference><Citation>Office for National Statistics (ONS), released 30 March 2023, ONS website, statistical bulletin, Prevalence of ongoing symptoms following coronavirus (COVID-19) infection in the UK: 30 March 2023.</Citation></Reference><Reference><Citation>Long COVID is a serious health concern in Europe. Institute for Health Metrics and Evaluation. Available at https://www.healthdata.org/news-events/insights-blog/acting-data/long-covid-serious-health-concern-europe.</Citation></Reference><Reference><Citation>Cai J et al. A one-year follow-up study of systematic impact of long COVID symptoms among patients post SARS-CoV-2 omicron variants infection in Shanghai, China. Emerg Microbes Infect 12, 2220578 (2023). 10.1080/22221751.2023.2220578</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/22221751.2023.2220578</ArticleId><ArticleId IdType="pmc">PMC10281439</ArticleId><ArticleId IdType="pubmed">37272336</ArticleId></ArticleIdList></Reference><Reference><Citation>Mateu L et al. Determinants of the onset and prognosis of the post-COVID-19 condition: a 2-year prospective observational cohort study. Lancet Reg Health Eur 33, 100724 (2023). 10.1016/j.lanepe.2023.100724</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lanepe.2023.100724</ArticleId><ArticleId IdType="pmc">PMC10636281</ArticleId><ArticleId IdType="pubmed">37954002</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai M, Xie Y, Topol EJ &amp; Al-Aly Z Three-year outcomes of post-acute sequelae of COVID-19. Nature Medicine 30, 1564&#x2013;1573 (2024). 10.1038/s41591-024-02987-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-024-02987-8</ArticleId><ArticleId IdType="pmc">PMC11186764</ArticleId><ArticleId IdType="pubmed">38816608</ArticleId></ArticleIdList></Reference><Reference><Citation>Ford ND et al. Long COVID and Significant Activity Limitation Among Adults, by Age - United States, June 1&#x2013;13, 2022, to June 7&#x2013;19, 2023. MMWR Morb. Mortal. Wkly. Rep 72, 866&#x2013;870 (2023). 10.15585/mmwr.mm7232a3</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7232a3</ArticleId><ArticleId IdType="pmc">PMC10415000</ArticleId><ArticleId IdType="pubmed">37561665</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson EJ et al. Long COVID burden and risk factors in 10 UK longitudinal studies and electronic health records. Nat. Commun 13, 3528 (2022). 10.1038/s41467-022-30836-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-30836-0</ArticleId><ArticleId IdType="pmc">PMC9240035</ArticleId><ArticleId IdType="pubmed">35764621</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsampasian V et al. Risk Factors Associated With Post-COVID-19 Condition: A Systematic Review and Meta-analysis. JAMA Intern. Med (2023). 10.1001/jamainternmed.2023.0750</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamainternmed.2023.0750</ArticleId><ArticleId IdType="pmc">PMC10037203</ArticleId><ArticleId IdType="pubmed">36951832</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayoubkhani D Prevalence of ongoing symptoms following coronavirus (COVID-19) infection in the UK - Office for National Statistics. (2021).</Citation></Reference><Reference><Citation>Eligulashvili A et al. Patients with unmet social needs are at higher risks of developing severe long COVID-19 symptoms and neuropsychiatric sequela. Sci Rep 14, 7743 (2024). 10.1038/s41598-024-58430-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-024-58430-y</ArticleId><ArticleId IdType="pmc">PMC10987523</ArticleId><ArticleId IdType="pubmed">38565574</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheong J-G et al. Epigenetic memory of coronavirus infection in innate immune cells and their progenitors. Cell 186, 3882&#x2013;3902.e3824 (2023). 10.1016/j.cell.2023.07.019</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2023.07.019</ArticleId><ArticleId IdType="pmc">PMC10638861</ArticleId><ArticleId IdType="pubmed">37597510</ArticleId></ArticleIdList></Reference><Reference><Citation>Lammi V et al. Genome-wide Association Study of Long COVID. medRxiv, 2023.2006.2029.23292056 (2023). 10.1101/2023.06.29.23292056</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2023.06.29.23292056</ArticleId></ArticleIdList></Reference><Reference><Citation>Augusto DG et al. A common allele of HLA is associated with asymptomatic SARS-CoV-2 infection. Nature 620, 128&#x2013;136 (2023). 10.1038/s41586-023-06331-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-023-06331-x</ArticleId><ArticleId IdType="pmc">PMC10396966</ArticleId><ArticleId IdType="pubmed">37468623</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor K et al. Genetic risk factors for severe and fatigue dominant long COVID and commonalities with ME/CFS identified by combinatorial analysis. J Transl Med 21, 775 (2023). 10.1186/s12967-023-04588-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12967-023-04588-4</ArticleId><ArticleId IdType="pmc">PMC10621206</ArticleId><ArticleId IdType="pubmed">37915075</ArticleId></ArticleIdList></Reference><Reference><Citation>Morioka S et al. Post COVID-19 condition of the Omicron variant of SARS-CoV-2. J. Infect. Chemother 28, 1546&#x2013;1551 (2022). 10.1016/j.jiac.2022.08.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jiac.2022.08.007</ArticleId><ArticleId IdType="pmc">PMC9365517</ArticleId><ArticleId IdType="pubmed">35963600</ArticleId></ArticleIdList></Reference><Reference><Citation>Bowe B, Xie Y &amp; Al-Aly Z Acute and postacute sequelae associated with SARS-CoV-2 reinfection. Nature Medicine 28, 2398&#x2013;2405 (2022). 10.1038/s41591-022-02051-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-02051-3</ArticleId><ArticleId IdType="pmc">PMC9671810</ArticleId><ArticleId IdType="pubmed">36357676</ArticleId></ArticleIdList></Reference><Reference><Citation>Azzolini E et al. Association Between BNT162b2 Vaccination and Long COVID After Infections Not Requiring Hospitalization in Health Care Workers. JAMA (2022). 10.1001/jama.2022.11691</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2022.11691</ArticleId><ArticleId IdType="pmc">PMC9250078</ArticleId><ArticleId IdType="pubmed">35796131</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Aly Z, Bowe B &amp; Xie Y Long COVID after breakthrough SARS-CoV-2 infection. Nature Medicine 28, 1461&#x2013;1467 (2022). 10.1038/s41591-022-01840-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-01840-0</ArticleId><ArticleId IdType="pmc">PMC9307472</ArticleId><ArticleId IdType="pubmed">35614233</ArticleId></ArticleIdList></Reference><Reference><Citation>Catal&#xe0; M et al. The effectiveness of COVID-19 vaccines to prevent long COVID symptoms: staggered cohort study of data from the UK, Spain, and Estonia. Lancet Respir Med 12, 225&#x2013;236 (2024). 10.1016/s2213-2600(23)00414-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s2213-2600(23)00414-9</ArticleId><ArticleId IdType="pubmed">38219763</ArticleId></ArticleIdList></Reference><Reference><Citation>Malden DE et al. Post-COVID conditions following COVID-19 vaccination: a retrospective matched cohort study of patients with SARS-CoV-2 infection. Nat Commun 15, 4101 (2024). 10.1038/s41467-024-48022-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-024-48022-9</ArticleId><ArticleId IdType="pmc">PMC11111703</ArticleId><ArticleId IdType="pubmed">38778026</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie Y, Choi T &amp; Al-Aly Z Association of Treatment With Nirmatrelvir and the Risk of Post&#x2013;COVID-19 Condition. JAMA Intern. Med (2023). 10.1001/jamainternmed.2023.0743</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamainternmed.2023.0743</ArticleId><ArticleId IdType="pmc">PMC10037200</ArticleId><ArticleId IdType="pubmed">36951829</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie Y, Choi T &amp; Al-Aly Z Molnupiravir and risk of post-acute sequelae of covid-19: cohort study. BMJ 381, e074572 (2023). 10.1136/bmj-2022-074572</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj-2022-074572</ArticleId><ArticleId IdType="pmc">PMC10126525</ArticleId><ArticleId IdType="pubmed">37161995</ArticleId></ArticleIdList></Reference><Reference><Citation>Durstenfeld MS et al. Association of nirmatrelvir/ritonavir treatment with Long COVID symptoms in an online cohort of non-hospitalized individuals experiencing breakthrough SARS-CoV-2 infection in the omicron era. medRxiv (2023). 10.1101/2023.03.02.23286730</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2023.03.02.23286730</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel R et al. Incidence of symptoms associated with post-acute sequelae of SARS-CoV-2 infection in non-hospitalized vaccinated patients receiving Nirmatrelvir-ritonavir. medRxiv (2023). 10.1101/2023.04.05.23288196</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2023.04.05.23288196</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu S et al. Early Biological Markers of Post-Acute Sequelae of SARS-CoV-2 Infection. medRxiv, 2023.2007.2014.23292649 (2023). 10.1101/2023.07.14.23292649</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2023.07.14.23292649</ArticleId><ArticleId IdType="pmc">PMC11358427</ArticleId><ArticleId IdType="pubmed">39198441</ArticleId></ArticleIdList></Reference><Reference><Citation>Antar AAR et al. Long COVID brain fog and muscle pain are associated with longer time to clearance of SARS-CoV-2 RNA from the upper respiratory tract during acute infection. Front. Immunol 14, 1147549 (2023). 10.3389/fimmu.2023.1147549</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2023.1147549</ArticleId><ArticleId IdType="pmc">PMC10176965</ArticleId><ArticleId IdType="pubmed">37187756</ArticleId></ArticleIdList></Reference><Reference><Citation>Ozonoff A et al. Features of acute COVID-19 associated with post-acute sequelae of SARS-CoV-2 phenotypes: results from the IMPACC study. Nature Communications 15, 216 (2024). 10.1038/s41467-023-44090-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-023-44090-5</ArticleId><ArticleId IdType="pmc">PMC10764789</ArticleId><ArticleId IdType="pubmed">38172101</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso MJ et al. in Open forum infectious diseases Vol. 9 ofab640 (2022).</Citation></Reference><Reference><Citation>Kenny G et al. Identification of Distinct Long COVID Clinical Phenotypes Through Cluster Analysis of Self-Reported Symptoms. Open Forum Infect Dis 9, ofac060 (2022). 10.1093/ofid/ofac060</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ofid/ofac060</ArticleId><ArticleId IdType="pmc">PMC8900926</ArticleId><ArticleId IdType="pubmed">35265728</ArticleId></ArticleIdList></Reference><Reference><Citation>Gottlieb M et al. Long COVID Clinical Phenotypes up to 6 Months After Infection Identified by Latent Class Analysis of Self-Reported Symptoms. Open Forum Infectious Diseases 10 (2023). 10.1093/ofid/ofad277</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ofid/ofad277</ArticleId><ArticleId IdType="pmc">PMC10327879</ArticleId><ArticleId IdType="pubmed">37426952</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang H et al. Data-driven identification of post-acute SARS-CoV-2 infection subphenotypes. Nat. Med (2022). 10.1038/s41591-022-02116-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-02116-3</ArticleId><ArticleId IdType="pmc">PMC9873564</ArticleId><ArticleId IdType="pubmed">36456834</ArticleId></ArticleIdList></Reference><Reference><Citation>Choutka J, Jansari V, Hornig M &amp; Iwasaki A Unexplained post-acute infection syndromes. Nat. Med 28, 911&#x2013;923 (2022). 10.1038/s41591-022-01810-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-01810-6</ArticleId><ArticleId IdType="pubmed">35585196</ArticleId></ArticleIdList></Reference><Reference><Citation>Feder HM et al. A Critical Appraisal of &#x201c;Chronic Lyme Disease&#x201d;. N. Engl. J. Med 357, 1422&#x2013;1430 (2007). 10.1056/NEJMra072023</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra072023</ArticleId><ArticleId IdType="pubmed">17914043</ArticleId></ArticleIdList></Reference><Reference><Citation>The Clinical Assessment, Treatment, and Prevention of Lyme Disease, Human Granulocytic Anaplasmosis, and Babesiosis: Clinical Practice Guidelines by the Infectious Diseases Society of America. (University of Chicago Press, 2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">17029130</ArticleId></ArticleIdList></Reference><Reference><Citation>Bateman L et al. Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Essentials of Diagnosis and Management. Mayo Clin. Proc 96, 2861&#x2013;2878 (2021). 10.1016/j.mayocp.2021.07.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mayocp.2021.07.004</ArticleId><ArticleId IdType="pubmed">34454716</ArticleId></ArticleIdList></Reference><Reference><Citation>Wohl DA et al. Post-Ebola Symptoms 7 Years After Infection: The Natural History of Long Ebola. Clin. Infect. Dis 76, e835&#x2013;e840 (2023). 10.1093/cid/ciac732</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciac732</ArticleId><ArticleId IdType="pmc">PMC10169389</ArticleId><ArticleId IdType="pubmed">36065768</ArticleId></ArticleIdList></Reference><Reference><Citation>Litleskare S et al. Prevalence of Irritable Bowel Syndrome and Chronic Fatigue 10 Years After Giardia Infection. Clin. Gastroenterol. Hepatol 16, 1064&#x2013;1072.e1064 (2018). 10.1016/j.cgh.2018.01.022</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cgh.2018.01.022</ArticleId><ArticleId IdType="pubmed">29378314</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso MJ, Hanson MR, Deeks SG Infection-associated chronic conditions: why long COVID is our best chance to untangle Osler&#x2019;s web. Science Translational Medicine In press. (2024).</Citation></Reference><Reference><Citation>Bridges JP, Vladar EK, Huang H &amp; Mason RJ Respiratory epithelial cell responses to SARS-CoV-2 in COVID-19. Thorax 77, 203&#x2013;209 (2022). 10.1136/thoraxjnl-2021-217561</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/thoraxjnl-2021-217561</ArticleId><ArticleId IdType="pmc">PMC9273148</ArticleId><ArticleId IdType="pubmed">34404754</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamers MM et al. SARS-CoV-2 productively infects human gut enterocytes. Science 369, 50&#x2013;54 (2020). https://doi.org/doi:10.1126/science.abc1669</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abc1669</ArticleId><ArticleId IdType="pmc">PMC7199907</ArticleId><ArticleId IdType="pubmed">32358202</ArticleId></ArticleIdList></Reference><Reference><Citation>Perico L, Benigni A &amp; Remuzzi G SARS-CoV-2 and the spike protein in endotheliopathy. Trends in Microbiology 32, 53&#x2013;67 (2024). 10.1016/j.tim.2023.06.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tim.2023.06.004</ArticleId><ArticleId IdType="pmc">PMC10258582</ArticleId><ArticleId IdType="pubmed">37393180</ArticleId></ArticleIdList></Reference><Reference><Citation>Tissue expression of ACE2 - summary - the human protein atlas.</Citation></Reference><Reference><Citation>Stein SR et al. SARS-CoV-2 infection and persistence in the human body and brain at autopsy. Nature 612, 758&#x2013;763 (2022). 10.1038/s41586-022-05542-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-05542-y</ArticleId><ArticleId IdType="pmc">PMC9749650</ArticleId><ArticleId IdType="pubmed">36517603</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldberg SA et al. Viral Determinants of Acute COVID-19 Symptoms in a Nonhospitalized Adult Population in the Pre-Omicron Era. Open Forum Infect Dis 10, ofad396 (2023). 10.1093/ofid/ofad396</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ofid/ofad396</ArticleId><ArticleId IdType="pmc">PMC10456204</ArticleId><ArticleId IdType="pubmed">37636517</ArticleId></ArticleIdList></Reference><Reference><Citation>Tassetto M et al. Detection of Higher Cycle Threshold Values in Culturable SARS-CoV-2 Omicron BA.1 Sublineage Compared with Pre-Omicron Variant Specimens - San Francisco Bay Area, California, July 2021-March 2022. MMWR Morb. Mortal. Wkly. Rep 71, 1151&#x2013;1154 (2022). 10.15585/mmwr.mm7136a3</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7136a3</ArticleId><ArticleId IdType="pmc">PMC9470222</ArticleId><ArticleId IdType="pubmed">36074732</ArticleId></ArticleIdList></Reference><Reference><Citation>Laitman AM et al. The SARS-CoV-2 Omicron Variant Does Not Have Higher Nasal Viral Loads Compared to the Delta Variant in Symptomatic and Asymptomatic Individuals. J. Clin. Microbiol 60, e0013922 (2022). 10.1128/jcm.00139-22</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jcm.00139-22</ArticleId><ArticleId IdType="pmc">PMC9020334</ArticleId><ArticleId IdType="pubmed">35341324</ArticleId></ArticleIdList></Reference><Reference><Citation>Gottlieb M et al. Severe Fatigue and Persistent Symptoms at Three Months Following SARS-CoV-2 Infections During the Pre-Delta, Delta, and Omicron Time Periods: A Multicenter Prospective Cohort Study. Clin. Infect. Dis (2023). 10.1093/cid/ciad045</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciad045</ArticleId><ArticleId IdType="pmc">PMC10249989</ArticleId><ArticleId IdType="pubmed">36705268</ArticleId></ArticleIdList></Reference><Reference><Citation>Su Y et al. Multiple Early Factors Anticipate Post-Acute COVID-19 Sequelae. Cell 0 (2022). 10.1016/j.cell.2022.01.014</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2022.01.014</ArticleId><ArticleId IdType="pmc">PMC8786632</ArticleId><ArticleId IdType="pubmed">35216672</ArticleId></ArticleIdList></Reference><Reference><Citation>Malkova A et al. Post COVID-19 Syndrome in Patients with Asymptomatic/Mild Form. Pathogens 10 (2021). 10.3390/pathogens10111408</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pathogens10111408</ArticleId><ArticleId IdType="pmc">PMC8620929</ArticleId><ArticleId IdType="pubmed">34832564</ArticleId></ArticleIdList></Reference><Reference><Citation>Antar AAR &amp; Peluso MJ CROI 2023: Acute and Post-Acute COVID-19. Top. Antivir. Med 31, 493&#x2013;509 (2023). 10.1111/all.14657</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/all.14657</ArticleId><ArticleId IdType="pmc">PMC10266867</ArticleId><ArticleId IdType="pubmed">37315513</ArticleId></ArticleIdList></Reference><Reference><Citation>Bramante CT et al. Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial. The Lancet Infectious Diseases 23, 1119&#x2013;1129 (2023). 10.1016/S1473-3099(23)00299-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(23)00299-2</ArticleId><ArticleId IdType="pmc">PMC11259948</ArticleId><ArticleId IdType="pubmed">37302406</ArticleId></ArticleIdList></Reference><Reference><Citation>Bramante CT et al. Favorable Antiviral Effect of Metformin on Severe Acute Respiratory Syndrome Coronavirus 2 Viral Load in a Randomized, Placebo-Controlled Clinical Trial of Coronavirus Disease 2019. Clinical Infectious Diseases (2024). 10.1093/cid/ciae159</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciae159</ArticleId><ArticleId IdType="pmc">PMC11327787</ArticleId><ArticleId IdType="pubmed">38690892</ArticleId></ArticleIdList></Reference><Reference><Citation>Investigators A. et al. Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19. N. Engl. J. Med 385, 790&#x2013;802 (2021). 10.1056/NEJMoa2105911</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2105911</ArticleId><ArticleId IdType="pmc">PMC8362594</ArticleId><ArticleId IdType="pubmed">34351721</ArticleId></ArticleIdList></Reference><Reference><Citation>Investigators R.-C. et al. Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19. N. Engl. J. Med 385, 777&#x2013;789 (2021). 10.1056/NEJMoa2103417</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2103417</ArticleId><ArticleId IdType="pmc">PMC8362592</ArticleId><ArticleId IdType="pubmed">34351722</ArticleId></ArticleIdList></Reference><Reference><Citation>Group R. C. Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet 399, 143&#x2013;151 (2022). 10.1016/S0140-6736(21)01825-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)01825-0</ArticleId><ArticleId IdType="pmc">PMC8598213</ArticleId><ArticleId IdType="pubmed">34800427</ArticleId></ArticleIdList></Reference><Reference><Citation>Berger JS et al. Effect of P2Y12 Inhibitors on Survival Free of Organ Support Among Non-Critically Ill Hospitalized Patients With COVID-19: A Randomized Clinical Trial. JAMA 327, 227&#x2013;236 (2022). 10.1001/jama.2021.23605</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2021.23605</ArticleId><ArticleId IdType="pmc">PMC8767444</ArticleId><ArticleId IdType="pubmed">35040887</ArticleId></ArticleIdList></Reference><Reference><Citation>Connors JM et al. Effect of Antithrombotic Therapy on Clinical Outcomes in Outpatients With Clinically Stable Symptomatic COVID-19: The ACTIV-4B Randomized Clinical Trial. JAMA 326, 1703&#x2013;1712 (2021). 10.1001/jama.2021.17272</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2021.17272</ArticleId><ArticleId IdType="pmc">PMC8506296</ArticleId><ArticleId IdType="pubmed">34633405</ArticleId></ArticleIdList></Reference><Reference><Citation>Writing Committee for the, R.-C. A. P. I. et al. Long-term (180-Day) Outcomes in Critically Ill Patients With COVID-19 in the REMAP-CAP Randomized Clinical Trial. JAMA 329, 39&#x2013;51 (2023). 10.1001/jama.2022.23257</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2022.23257</ArticleId><ArticleId IdType="pmc">PMC9857594</ArticleId><ArticleId IdType="pubmed">36525245</ArticleId></ArticleIdList></Reference><Reference><Citation>Hammond J et al. Nirmatrelvir for Vaccinated or Unvaccinated Adult Outpatients with Covid-19. N Engl J Med 390, 1186&#x2013;1195 (2024). 10.1056/NEJMoa2309003</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2309003</ArticleId><ArticleId IdType="pmc">PMC11156287</ArticleId><ArticleId IdType="pubmed">38598573</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaebler C et al. Evolution of antibody immunity to SARS-CoV-2. Nature (2021). 10.1038/s41586-021-03207-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03207-w</ArticleId><ArticleId IdType="pmc">PMC8221082</ArticleId><ArticleId IdType="pubmed">33461210</ArticleId></ArticleIdList></Reference><Reference><Citation>Aydillo T et al. Shedding of Viable SARS-CoV-2 after Immunosuppressive Therapy for Cancer. N. Engl. J. Med 383, 2586&#x2013;2588 (2020). 10.1056/NEJMc2031670</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2031670</ArticleId><ArticleId IdType="pmc">PMC7722690</ArticleId><ArticleId IdType="pubmed">33259154</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi B et al. Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host. N. Engl. J. Med 383, 2291&#x2013;2293 (2020). 10.1056/NEJMc2031364</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2031364</ArticleId><ArticleId IdType="pmc">PMC7673303</ArticleId><ArticleId IdType="pubmed">33176080</ArticleId></ArticleIdList></Reference><Reference><Citation>Zollner A et al. Postacute COVID-19 is Characterized by Gut Viral Antigen Persistence in Inflammatory Bowel Diseases. Gastroenterology 163, 495&#x2013;506.e498 (2022). 10.1053/j.gastro.2022.04.037</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2022.04.037</ArticleId><ArticleId IdType="pmc">PMC9057012</ArticleId><ArticleId IdType="pubmed">35508284</ArticleId></ArticleIdList></Reference><Reference><Citation>Natarajan A et al. Gastrointestinal symptoms and fecal shedding of SARS-CoV-2 RNA suggest prolonged gastrointestinal infection. Med (N Y) (2022). 10.1016/j.medj.2022.04.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.medj.2022.04.001</ArticleId><ArticleId IdType="pmc">PMC9005383</ArticleId><ArticleId IdType="pubmed">35434682</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Q et al. Adaptive immune responses to SARS-CoV-2 persist in the pharyngeal lymphoid tissue of children. Nat. Immunol 24, 186&#x2013;199 (2023). 10.1038/s41590-022-01367-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-022-01367-z</ArticleId><ArticleId IdType="pmc">PMC10777159</ArticleId><ArticleId IdType="pubmed">36536106</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheung CCL et al. Residual SARS-CoV-2 viral antigens detected in GI and hepatic tissues from five recovered patients with COVID-19. Gut 71, 226&#x2013;229 (2022). 10.1136/gutjnl-2021-324280</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2021-324280</ArticleId><ArticleId IdType="pubmed">34083386</ArticleId></ArticleIdList></Reference><Reference><Citation>Goh D et al. Case report: Persistence of residual antigen and RNA of the SARS-CoV-2 virus in tissues of two patients with long COVID. Front. Immunol 13, 939989 (2022). 10.3389/fimmu.2022.939989</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.939989</ArticleId><ArticleId IdType="pmc">PMC9483160</ArticleId><ArticleId IdType="pubmed">36131932</ArticleId></ArticleIdList></Reference><Reference><Citation>Swank Z et al. Persistent circulating SARS-CoV-2 spike is associated with post-acute COVID-19 sequelae. Clin. Infect. Dis (2022). 10.1093/cid/ciac722</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciac722</ArticleId><ArticleId IdType="pmc">PMC10169416</ArticleId><ArticleId IdType="pubmed">36052466</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso MJ et al. Plasma-based antigen persistence in the post-acute phase of COVID-19. The Lancet Infectious Diseases 24, e345&#x2013;e347 (2024). 10.1016/S1473-3099(24)00211-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(24)00211-1</ArticleId><ArticleId IdType="pubmed">38604216</ArticleId></ArticleIdList></Reference><Reference><Citation>Menezes SM et al. Blood transcriptomic analyses reveal persistent SARS-CoV-2 RNA and candidate biomarkers in post-COVID-19 condition. The Lancet Microbe 10.1016/S2666-5247(24)00055-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2666-5247(24)00055-7</ArticleId><ArticleId IdType="pubmed">38677304</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodriguez L et al. Restrained memory CD8+ T cell responses favors viral persistence and elevated IgG responses in patients with severe Long COVID. medRxiv, 2024.2002.2011.24302636 (2024). 10.1101/2024.02.11.24302636</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2024.02.11.24302636</ArticleId></ArticleIdList></Reference><Reference><Citation>Fern&#xe1;ndez-de-Las-Pe&#xf1;as C et al. Presence of SARS-CoV-2 RNA in COVID-19 survivors with post-COVID symptoms 2 years after hospitalization: The VIPER study. J Med Virol 96, e29676 (2024). 10.1002/jmv.29676</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.29676</ArticleId><ArticleId IdType="pubmed">38747018</ArticleId></ArticleIdList></Reference><Reference><Citation>Griffin DE Why does viral RNA sometimes persist after recovery from acute infections? PLoS Biol. 20, e3001687 (2022). 10.1371/journal.pbio.3001687</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pbio.3001687</ArticleId><ArticleId IdType="pmc">PMC9191737</ArticleId><ArticleId IdType="pubmed">35648781</ArticleId></ArticleIdList></Reference><Reference><Citation>Kipar A, Meli ML, Baptiste KE, Bowker LJ &amp; Lutz H Sites of feline coronavirus persistence in healthy cats. J Gen Virol 91, 1698&#x2013;1707 (2010). 10.1099/vir.0.020214-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/vir.0.020214-0</ArticleId><ArticleId IdType="pubmed">20237226</ArticleId></ArticleIdList></Reference><Reference><Citation>Vogel L et al. Pathogenic characteristics of persistent feline enteric coronavirus infection in cats. Vet Res 41, 71 (2010). 10.1051/vetres/2010043</Citation><ArticleIdList><ArticleId IdType="doi">10.1051/vetres/2010043</ArticleId><ArticleId IdType="pmc">PMC2939696</ArticleId><ArticleId IdType="pubmed">20663472</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuo W et al. The persistence of SARS-CoV-2 in tissues and its association with long COVID symptoms: a cross-sectional cohort study in China. The Lancet Infectious Diseases 10.1016/S1473-3099(24)00171-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(24)00171-3</ArticleId><ArticleId IdType="pubmed">38663423</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin JC et al. SARS CoV-2 detected in neonatal stool remote from maternal COVID-19 during pregnancy. Pediatr. Res, 1&#x2013;8 (2022). 10.1038/s41390-022-02266-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41390-022-02266-7</ArticleId><ArticleId IdType="pmc">PMC9388973</ArticleId><ArticleId IdType="pubmed">35986143</ArticleId></ArticleIdList></Reference><Reference><Citation>Appelman B et al. Muscle abnormalities worsen after post-exertional malaise in long COVID. Nature Communications 15, 17 (2024). 10.1038/s41467-023-44432-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-023-44432-3</ArticleId><ArticleId IdType="pmc">PMC10766651</ArticleId><ArticleId IdType="pubmed">38177128</ArticleId></ArticleIdList></Reference><Reference><Citation>Mart&#xed;nez-Col&#xf3;n GJ et al. SARS-CoV-2 infection drives an inflammatory response in human adipose tissue through infection of adipocytes and macrophages. Sci. Transl. Med 14, eabm9151 (2022). 10.1126/scitranslmed.abm9151</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.abm9151</ArticleId><ArticleId IdType="pmc">PMC9529056</ArticleId><ArticleId IdType="pubmed">36137009</ArticleId></ArticleIdList></Reference><Reference><Citation>Perico L, Benigni A &amp; Remuzzi G SARS-CoV-2 and the spike protein in endotheliopathy. Trends Microbiol. (2023). 10.1016/j.tim.2023.06.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tim.2023.06.004</ArticleId><ArticleId IdType="pmc">PMC10258582</ArticleId><ArticleId IdType="pubmed">37393180</ArticleId></ArticleIdList></Reference><Reference><Citation>Tejerina F et al. Post-COVID-19 syndrome. SARS-CoV-2 RNA detection in plasma, stool, and urine in patients with persistent symptoms after COVID-19. BMC Infect. Dis 22, 211 (2022). 10.1186/s12879-022-07153-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-022-07153-4</ArticleId><ArticleId IdType="pmc">PMC8892394</ArticleId><ArticleId IdType="pubmed">35240997</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso MJ et al. Multimodal Molecular Imaging Reveals Tissue-Based T Cell Activation and Viral RNA Persistence for Up to 2 Years Following COVID-19. Science Translational Medicine (2024). 10.1101/2023.07.27.23293177</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2023.07.27.23293177</ArticleId><ArticleId IdType="pmc">PMC11337933</ArticleId><ArticleId IdType="pubmed">38959327</ArticleId></ArticleIdList></Reference><Reference><Citation>Fern&#xe1;ndez-de-Las-Pe&#xf1;as C et al. Presence of SARS-CoV-2 RNA in COVID-19 survivors with post-COVID symptoms: a systematic review of the literature. Clin Chem Lab Med 62, 1044&#x2013;1052 (2024). 10.1515/cclm-2024-0036</Citation><ArticleIdList><ArticleId IdType="doi">10.1515/cclm-2024-0036</ArticleId><ArticleId IdType="pubmed">38366966</ArticleId></ArticleIdList></Reference><Reference><Citation>Geng LN et al. Nirmatrelvir-Ritonavir and Symptoms in Adults With Postacute Sequelae of SARS-CoV-2 Infection: The STOP-PASC Randomized Clinical Trial. JAMA Intern Med (2024). 10.1001/jamainternmed.2024.2007</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamainternmed.2024.2007</ArticleId><ArticleId IdType="pmc">PMC11161857</ArticleId><ArticleId IdType="pubmed">38848477</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen AK et al. Impact of extended-course oral nirmatrelvir/ritonavir (Paxlovid) in established Long COVID: Case series and research considerations. Res Sq (2023). 10.21203/rs.3.rs-3359429/v1</Citation><ArticleIdList><ArticleId IdType="doi">10.21203/rs.3.rs-3359429/v1</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor PC et al. Neutralizing monoclonal antibodies for treatment of COVID-19. Nat. Rev. Immunol 21, 382&#x2013;393 (2021). 10.1038/s41577-021-00542-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-021-00542-x</ArticleId><ArticleId IdType="pmc">PMC8054133</ArticleId><ArticleId IdType="pubmed">33875867</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheppke KA et al. Remission of severe forms of long COVID following monoclonal antibody (MCA) infusions: A report of signal index cases and call for targeted research. Am J Emerg Med 75, 122&#x2013;127 (2024). 10.1016/j.ajem.2023.09.051</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajem.2023.09.051</ArticleId><ArticleId IdType="pubmed">37944296</ArticleId></ArticleIdList></Reference><Reference><Citation>Willerson JT &amp; Ridker PM Inflammation as a cardiovascular risk factor. Circulation 109, II2&#x2013;10 (2004). 10.1161/01.CIR.0000129535.04194.38</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.CIR.0000129535.04194.38</ArticleId><ArticleId IdType="pubmed">15173056</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H et al. Cytomegalovirus Infection and Relative Risk of Cardiovascular Disease (Ischemic Heart Disease, Stroke, and Cardiovascular Death): A Meta-Analysis of Prospective Studies Up to 2016. J. Am. Heart Assoc 6 (2017). 10.1161/JAHA.116.005025</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/JAHA.116.005025</ArticleId><ArticleId IdType="pmc">PMC5586265</ArticleId><ArticleId IdType="pubmed">28684641</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsue PY &amp; Waters DD HIV infection and coronary heart disease: mechanisms and management. Nat. Rev. Cardiol 16, 745&#x2013;759 (2019). 10.1038/s41569-019-0219-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41569-019-0219-9</ArticleId><ArticleId IdType="pmc">PMC8015945</ArticleId><ArticleId IdType="pubmed">31182833</ArticleId></ArticleIdList></Reference><Reference><Citation>Lucas C et al. Longitudinal analyses reveal immunological misfiring in severe COVID-19. Nature 584, 463&#x2013;469 (2020). 10.1038/s41586-020-2588-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2588-y</ArticleId><ArticleId IdType="pmc">PMC7477538</ArticleId><ArticleId IdType="pubmed">32717743</ArticleId></ArticleIdList></Reference><Reference><Citation>Del Valle DM et al. An inflammatory cytokine signature predicts COVID-19 severity and survival. Nat. Med 26, 1636&#x2013;1643 (2020). 10.1038/s41591-020-1051-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-020-1051-9</ArticleId><ArticleId IdType="pmc">PMC7869028</ArticleId><ArticleId IdType="pubmed">32839624</ArticleId></ArticleIdList></Reference><Reference><Citation>Phetsouphanh C et al. Improvement of immune dysregulation in individuals with long COVID at 24-months following SARS-CoV-2 infection. Nat Commun 15, 3315 (2024). 10.1038/s41467-024-47720-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-024-47720-8</ArticleId><ArticleId IdType="pmc">PMC11024141</ArticleId><ArticleId IdType="pubmed">38632311</ArticleId></ArticleIdList></Reference><Reference><Citation>Talla A et al. Persistent serum protein signatures define an inflammatory subcategory of long COVID. Nature Communications 14, 3417 (2023). 10.1038/s41467-023-38682-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-023-38682-4</ArticleId><ArticleId IdType="pmc">PMC10252177</ArticleId><ArticleId IdType="pubmed">37296110</ArticleId></ArticleIdList></Reference><Reference><Citation>Woodruff MC et al. Chronic inflammation, neutrophil activity, and autoreactivity splits long COVID. Nature Communications 14, 4201 (2023). 10.1038/s41467-023-40012-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-023-40012-7</ArticleId><ArticleId IdType="pmc">PMC10349085</ArticleId><ArticleId IdType="pubmed">37452024</ArticleId></ArticleIdList></Reference><Reference><Citation>Liew F et al. Large-scale phenotyping of patients with long COVID post-hospitalization reveals mechanistic subtypes of disease. Nat Immunol 25, 607&#x2013;621 (2024). 10.1038/s41590-024-01778-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-024-01778-0</ArticleId><ArticleId IdType="pmc">PMC11003868</ArticleId><ArticleId IdType="pubmed">38589621</ArticleId></ArticleIdList></Reference><Reference><Citation>Schulthei&#xdf; C et al. The IL-1&#x3b2;, IL-6, and TNF cytokine triad is associated with post-acute sequelae of COVID-19. Cell Rep Med 3, 100663 (2022). 10.1016/j.xcrm.2022.100663</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xcrm.2022.100663</ArticleId><ArticleId IdType="pmc">PMC9214726</ArticleId><ArticleId IdType="pubmed">35732153</ArticleId></ArticleIdList></Reference><Reference><Citation>Park J et al. Elevated circulating monocytes and monocyte activation in COVID-19 convalescent individuals. Front. Immunol 14, 1151780 (2023). 10.3389/fimmu.2023.1151780</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2023.1151780</ArticleId><ArticleId IdType="pmc">PMC10106598</ArticleId><ArticleId IdType="pubmed">37077911</ArticleId></ArticleIdList></Reference><Reference><Citation>Scott NA et al. Monocyte migration profiles define disease severity in acute COVID-19 and unique features of long COVID. Eur. Respir. J 61 (2023). 10.1183/13993003.02226-2022</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/13993003.02226-2022</ArticleId><ArticleId IdType="pmc">PMC10040898</ArticleId><ArticleId IdType="pubmed">36922030</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso MJ et al. Markers of Immune Activation and Inflammation in Individuals With Postacute Sequelae of Severe Acute Respiratory Syndrome Coronavirus 2 Infection. J. Infect. Dis (2021). 10.1093/infdis/jiab490</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiab490</ArticleId><ArticleId IdType="pmc">PMC8643408</ArticleId><ArticleId IdType="pubmed">34677601</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso MJ et al. Plasma Markers of Neurologic Injury and Inflammation in People With Self-Reported Neurologic Postacute Sequelae of SARS-CoV-2 Infection. Neurol Neuroimmunol Neuroinflamm 9 (2022). 10.1212/NXI.0000000000200003</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/NXI.0000000000200003</ArticleId><ArticleId IdType="pmc">PMC9210548</ArticleId><ArticleId IdType="pubmed">35701186</ArticleId></ArticleIdList></Reference><Reference><Citation>Durstenfeld MS et al. Role of antibodies, inflammatory markers, and echocardiographic findings in postacute cardiopulmonary symptoms after SARS-CoV-2 infection. JCI Insight 7 (2022). 10.1172/jci.insight.157053</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.157053</ArticleId><ArticleId IdType="pmc">PMC9220849</ArticleId><ArticleId IdType="pubmed">35389890</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun B et al. Characterization and Biomarker Analyses of Post-COVID-19 Complications and Neurological Manifestations. Cells 10 (2021). 10.3390/cells10020386</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells10020386</ArticleId><ArticleId IdType="pmc">PMC7918597</ArticleId><ArticleId IdType="pubmed">33668514</ArticleId></ArticleIdList></Reference><Reference><Citation>Saito S et al. Metabolomic and immune alterations in long COVID patients with chronic fatigue syndrome. Front Immunol 15, 1341843 (2024). 10.3389/fimmu.2024.1341843</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2024.1341843</ArticleId><ArticleId IdType="pmc">PMC10830702</ArticleId><ArticleId IdType="pubmed">38304426</ArticleId></ArticleIdList></Reference><Reference><Citation>Greene C et al. Blood&#x2013;brain barrier disruption and sustained systemic inflammation in individuals with long COVID-associated cognitive impairment. Nature Neuroscience 27, 421&#x2013;432 (2024). 10.1038/s41593-024-01576-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-024-01576-9</ArticleId><ArticleId IdType="pmc">PMC10917679</ArticleId><ArticleId IdType="pubmed">38388736</ArticleId></ArticleIdList></Reference><Reference><Citation>Junqueira C et al. Fc&#x3b3;R-mediated SARS-CoV-2 infection of monocytes activates inflammation. Nature 606, 576&#x2013;584 (2022). 10.1038/s41586-022-04702-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-04702-4</ArticleId><ArticleId IdType="pmc">PMC10071495</ArticleId><ArticleId IdType="pubmed">35385861</ArticleId></ArticleIdList></Reference><Reference><Citation>Patterson BK et al. Persistence of SARS CoV-2 S1 Protein in CD16+ Monocytes in Post-Acute Sequelae of COVID-19 (PASC) up to 15 Months Post-Infection. Front. Immunol 12, 746021 (2021). 10.3389/fimmu.2021.746021</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.746021</ArticleId><ArticleId IdType="pmc">PMC8784688</ArticleId><ArticleId IdType="pubmed">35082777</ArticleId></ArticleIdList></Reference><Reference><Citation>Phetsouphanh C et al. Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection. Nat. Immunol, 1&#x2013;7 (2022). 10.1038/s41590-021-01113-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-021-01113-x</ArticleId><ArticleId IdType="pubmed">35027728</ArticleId></ArticleIdList></Reference><Reference><Citation>LaVergne SM et al. Persistent CD8(+) T cell proliferation and activation in COVID-19 adult survivors with post-acute sequelae: a longitudinal, observational cohort study of persistent symptoms and T cell markers. Front Immunol 14, 1303971 (2023). 10.3389/fimmu.2023.1303971</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2023.1303971</ArticleId><ArticleId IdType="pmc">PMC10848319</ArticleId><ArticleId IdType="pubmed">38327763</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso MJ et al. Long-term SARS-CoV-2-specific immune and inflammatory responses in individuals recovering from COVID-19 with and without post-acute symptoms. Cell Rep., 109518 (2021). 10.1016/j.celrep.2021.109518</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2021.109518</ArticleId><ArticleId IdType="pmc">PMC8342976</ArticleId><ArticleId IdType="pubmed">34358460</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin K et al. Long COVID manifests with T cell dysregulation, inflammation and an uncoordinated adaptive immune response to SARS-CoV-2. Nature Immunology 25, 218&#x2013;225 (2024). 10.1038/s41590-023-01724-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-023-01724-6</ArticleId><ArticleId IdType="pmc">PMC10834368</ArticleId><ArticleId IdType="pubmed">38212464</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein J et al. Distinguishing features of Long COVID identified through immune profiling. Nature (2023). 10.1038/s41586-023-06651-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-023-06651-y</ArticleId><ArticleId IdType="pmc">PMC10620090</ArticleId><ArticleId IdType="pubmed">37748514</ArticleId></ArticleIdList></Reference><Reference><Citation>Weinstock LB et al. Mast cell activation symptoms are prevalent in Long-COVID. Int. J. Infect. Dis 112, 217&#x2013;226 (2021). 10.1016/j.ijid.2021.09.043</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2021.09.043</ArticleId><ArticleId IdType="pmc">PMC8459548</ArticleId><ArticleId IdType="pubmed">34563706</ArticleId></ArticleIdList></Reference><Reference><Citation>Verger A et al. 2-[18F]-FDG PET for imaging brain involvement in patients with long COVID: perspective of the EANM Neuroimaging Committee. Eur. J. Nucl. Med. Mol. Imaging 49, 3599&#x2013;3606 (2022). 10.1007/s00259-022-05913-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00259-022-05913-7</ArticleId><ArticleId IdType="pmc">PMC9286958</ArticleId><ArticleId IdType="pubmed">35840817</ArticleId></ArticleIdList></Reference><Reference><Citation>Debs P et al. Post-COVID-19 Brain [18F] FDG-PET Findings: A Retrospective Single-Center Study in the United States. AJNR Am. J. Neuroradiol 44, 517&#x2013;522 (2023). 10.3174/ajnr.A7863</Citation><ArticleIdList><ArticleId IdType="doi">10.3174/ajnr.A7863</ArticleId><ArticleId IdType="pmc">PMC10171380</ArticleId><ArticleId IdType="pubmed">37105680</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrucci R et al. Brain positron emission tomography (PET) and cognitive abnormalities one year after COVID-19. J. Neurol 270, 1823&#x2013;1834 (2023). 10.1007/s00415-022-11543-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-022-11543-8</ArticleId><ArticleId IdType="pmc">PMC9873215</ArticleId><ArticleId IdType="pubmed">36692636</ArticleId></ArticleIdList></Reference><Reference><Citation>Martini AL et al. Time-dependent recovery of brain hypometabolism in neuro-COVID-19 patients. Eur. J. Nucl. Med. Mol. Imaging 50, 90&#x2013;102 (2022). 10.1007/s00259-022-05942-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00259-022-05942-2</ArticleId><ArticleId IdType="pmc">PMC9388976</ArticleId><ArticleId IdType="pubmed">35984451</ArticleId></ArticleIdList></Reference><Reference><Citation>Goehringer F et al. Brain 18F-FDG PET imaging in outpatients with post-COVID-19 conditions: findings and associations with clinical characteristics. Eur. J. Nucl. Med. Mol. Imaging 50, 1084&#x2013;1089 (2023). 10.1007/s00259-022-06013-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00259-022-06013-2</ArticleId><ArticleId IdType="pmc">PMC9628394</ArticleId><ArticleId IdType="pubmed">36322190</ArticleId></ArticleIdList></Reference><Reference><Citation>Omidvari N et al. First-in-human immunoPET imaging of COVID-19 convalescent patients using dynamic total-body PET and a CD8-targeted minibody. medRxiv (2023). 10.1101/2023.03.14.23287121</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2023.03.14.23287121</ArticleId><ArticleId IdType="pmc">PMC10569706</ArticleId><ArticleId IdType="pubmed">37824612</ArticleId></ArticleIdList></Reference><Reference><Citation>VanElzakker MB et al. Neuroinflammation in post-acute sequelae of COVID-19 (PASC) as assessed by [11C]PBR28 PET correlates with vascular disease measures. Brain, Behavior, and Immunity 119, 713&#x2013;723 (2024). https://doi.org/10.1016/j.bbi.2024.04.015</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2024.04.015</ArticleId><ArticleId IdType="pmc">PMC11225883</ArticleId><ArticleId IdType="pubmed">38642615</ArticleId></ArticleIdList></Reference><Reference><Citation>Dantzer R Cytokine, sickness behavior, and depression. Immunol. Allergy Clin. North Am 29, 247&#x2013;264 (2009). 10.1016/j.iac.2009.02.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.iac.2009.02.002</ArticleId><ArticleId IdType="pmc">PMC2740752</ArticleId><ArticleId IdType="pubmed">19389580</ArticleId></ArticleIdList></Reference><Reference><Citation>Visvabharathy L, Orban ZS &amp; Koralnik IJ Case report: Treatment of long COVID with a SARS-CoV-2 antiviral and IL-6 blockade in a patient with rheumatoid arthritis and SARS-CoV-2 antigen persistence. Front. Med 9, 1003103 (2022). 10.3389/fmed.2022.1003103</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2022.1003103</ArticleId><ArticleId IdType="pmc">PMC9537824</ArticleId><ArticleId IdType="pubmed">36213654</ArticleId></ArticleIdList></Reference><Reference><Citation>Mourad A et al. Dexamethasone for Inpatients With COVID-19 in a National Cohort. JAMA Netw Open 6, e238516 (2023). 10.1001/jamanetworkopen.2023.8516</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2023.8516</ArticleId><ArticleId IdType="pmc">PMC10111178</ArticleId><ArticleId IdType="pubmed">37067800</ArticleId></ArticleIdList></Reference><Reference><Citation>Group R. C. et al. Dexamethasone in Hospitalized Patients with Covid-19. N. Engl. J. Med 384, 693&#x2013;704 (2021). 10.1056/NEJMoa2021436</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2021436</ArticleId><ArticleId IdType="pmc">PMC7383595</ArticleId><ArticleId IdType="pubmed">32678530</ArticleId></ArticleIdList></Reference><Reference><Citation>Marconi VC et al. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial. Lancet Respir Med 9, 1407&#x2013;1418 (2021). 10.1016/S2213-2600(21)00331-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(21)00331-3</ArticleId><ArticleId IdType="pmc">PMC8409066</ArticleId><ArticleId IdType="pubmed">34480861</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalil AC et al. Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19. N. Engl. J. Med 384, 795&#x2013;807 (2021). 10.1056/NEJMoa2031994</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2031994</ArticleId><ArticleId IdType="pmc">PMC7745180</ArticleId><ArticleId IdType="pubmed">33306283</ArticleId></ArticleIdList></Reference><Reference><Citation>Bronte V et al. Baricitinib restrains the immune dysregulation in patients with severe COVID-19. J. Clin. Invest 130, 6409&#x2013;6416 (2020). 10.1172/JCI141772</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI141772</ArticleId><ArticleId IdType="pmc">PMC8016181</ArticleId><ArticleId IdType="pubmed">32809969</ArticleId></ArticleIdList></Reference><Reference><Citation>Mannick JB &amp; Lamming DW Targeting the biology of aging with mTOR inhibitors. Nature Aging 3, 642&#x2013;660 (2023). 10.1038/s43587-023-00416-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s43587-023-00416-y</ArticleId><ArticleId IdType="pmc">PMC10330278</ArticleId><ArticleId IdType="pubmed">37142830</ArticleId></ArticleIdList></Reference><Reference><Citation>Marchetti C et al. OLT1177, a &#x3b2;-sulfonyl nitrile compound, safe in humans, inhibits the NLRP3 inflammasome and reverses the metabolic cost of inflammation. Proc. Natl. Acad. Sci. U. S. A 115, E1530&#x2013;E1539 (2018). 10.1073/pnas.1716095115</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1716095115</ArticleId><ArticleId IdType="pmc">PMC5816172</ArticleId><ArticleId IdType="pubmed">29378952</ArticleId></ArticleIdList></Reference><Reference><Citation>Abani O et al. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet 397, 1637&#x2013;1645 (2021). 10.1016/S0140-6736(21)00676-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)00676-0</ArticleId><ArticleId IdType="pmc">PMC8084355</ArticleId><ArticleId IdType="pubmed">33933206</ArticleId></ArticleIdList></Reference><Reference><Citation>Lescure F-X et al. Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med 9, 522&#x2013;532 (2021). 10.1016/S2213-2600(21)00099-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(21)00099-0</ArticleId><ArticleId IdType="pmc">PMC8078879</ArticleId><ArticleId IdType="pubmed">33676590</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuo Y et al. Prothrombotic autoantibodies in serum from patients hospitalized with COVID-19. Sci. Transl. Med 12 (2020). 10.1126/scitranslmed.abd3876</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.abd3876</ArticleId><ArticleId IdType="pmc">PMC7724273</ArticleId><ArticleId IdType="pubmed">33139519</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang SE et al. New-onset IgG autoantibodies in hospitalized patients with COVID-19. Nat. Commun 12, 5417 (2021). 10.1038/s41467-021-25509-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-25509-3</ArticleId><ArticleId IdType="pmc">PMC8440763</ArticleId><ArticleId IdType="pubmed">34521836</ArticleId></ArticleIdList></Reference><Reference><Citation>Woodruff MC et al. Dysregulated na&#xef;ve B cells and de novo autoreactivity in severe COVID-19. Nature (2022). 10.1038/s41586-022-05273-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-05273-0</ArticleId><ArticleId IdType="pmc">PMC9630115</ArticleId><ArticleId IdType="pubmed">36044993</ArticleId></ArticleIdList></Reference><Reference><Citation>Bastard P et al. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science 370 (2020). 10.1126/science.abd4585</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abd4585</ArticleId><ArticleId IdType="pmc">PMC7857397</ArticleId><ArticleId IdType="pubmed">32972996</ArticleId></ArticleIdList></Reference><Reference><Citation>Bastard P et al. Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths. Sci Immunol 6 (2021). 10.1126/sciimmunol.abl4340</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciimmunol.abl4340</ArticleId><ArticleId IdType="pmc">PMC8521484</ArticleId><ArticleId IdType="pubmed">34413139</ArticleId></ArticleIdList></Reference><Reference><Citation>Vazquez SE et al. Neutralizing Autoantibodies to Type I Interferons in COVID-19 Convalescent Donor Plasma. J. Clin. Immunol 41, 1169&#x2013;1171 (2021). 10.1007/s10875-021-01060-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10875-021-01060-0</ArticleId><ArticleId IdType="pmc">PMC8132742</ArticleId><ArticleId IdType="pubmed">34009544</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Wijst MGP et al. Type I interferon autoantibodies are associated with systemic immune alterations in patients with COVID-19. Sci. Transl. Med 13, eabh2624 (2021). 10.1126/scitranslmed.abh2624</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.abh2624</ArticleId><ArticleId IdType="pmc">PMC8601717</ArticleId><ArticleId IdType="pubmed">34429372</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y et al. Coagulopathy and Antiphospholipid Antibodies in Patients with Covid-19. N. Engl. J. Med 382, e38 (2020). 10.1056/NEJMc2007575</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2007575</ArticleId><ArticleId IdType="pmc">PMC7161262</ArticleId><ArticleId IdType="pubmed">32268022</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang EY et al. Diverse functional autoantibodies in patients with COVID-19. Nature 595, 283&#x2013;288 (2021). 10.1038/s41586-021-03631-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03631-y</ArticleId><ArticleId IdType="pubmed">34010947</ArticleId></ArticleIdList></Reference><Reference><Citation>Peng K et al. Risk of autoimmune diseases following COVID-19 and the potential protective effect from vaccination: a population-based cohort study. eClinicalMedicine 63, 102154 (2023). 10.1016/j.eclinm.2023.102154</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2023.102154</ArticleId><ArticleId IdType="pmc">PMC10458663</ArticleId><ArticleId IdType="pubmed">37637754</ArticleId></ArticleIdList></Reference><Reference><Citation>Tesch F et al. Incident autoimmune diseases in association with a SARS-CoV-2 infection: A matched cohort study. bioRxiv (2023). 10.1101/2023.01.25.23285014</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2023.01.25.23285014</ArticleId><ArticleId IdType="pmc">PMC10497688</ArticleId><ArticleId IdType="pubmed">37335408</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang R et al. Risk of autoimmune diseases in patients with COVID-19: A retrospective cohort study. EClinicalMedicine 56, 101783 (2023). 10.1016/j.eclinm.2022.101783</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2022.101783</ArticleId><ArticleId IdType="pmc">PMC9830133</ArticleId><ArticleId IdType="pubmed">36643619</ArticleId></ArticleIdList></Reference><Reference><Citation>Son K et al. Circulating anti-nuclear autoantibodies in COVID-19 survivors predict long-COVID symptoms. Eur. Respir. J (2022). 10.1183/13993003.00970-2022</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/13993003.00970-2022</ArticleId><ArticleId IdType="pmc">PMC9515477</ArticleId><ArticleId IdType="pubmed">36137590</ArticleId></ArticleIdList></Reference><Reference><Citation>See&#xdf;le J et al. Persistent symptoms in adult patients one year after COVID-19: a prospective cohort study. Clin. Infect. Dis (2021). 10.1093/cid/ciab611</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciab611</ArticleId><ArticleId IdType="pmc">PMC8394862</ArticleId><ArticleId IdType="pubmed">34223884</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso MJ, Thomas IJ, Munter SE, Deeks SG &amp; Henrich TJ Lack of Antinuclear Antibodies in Convalescent Coronavirus Disease 2019 Patients With Persistent Symptoms. Clin. Infect. Dis 74, 2083&#x2013;2084 (2022). 10.1093/cid/ciab890</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciab890</ArticleId><ArticleId IdType="pmc">PMC9187313</ArticleId><ArticleId IdType="pubmed">34617982</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein J et al. Distinguishing features of Long COVID identified through immune profiling. medRxiv (2022). 10.1101/2022.08.09.22278592</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2022.08.09.22278592</ArticleId><ArticleId IdType="pmc">PMC10620090</ArticleId><ArticleId IdType="pubmed">37748514</ArticleId></ArticleIdList></Reference><Reference><Citation>Pisetsky DS &amp; Lipsky PE New insights into the role of antinuclear antibodies in systemic lupus erythematosus. Nat. Rev. Rheumatol 16, 565&#x2013;579 (2020). 10.1038/s41584-020-0480-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41584-020-0480-7</ArticleId><ArticleId IdType="pmc">PMC8456518</ArticleId><ArticleId IdType="pubmed">32884126</ArticleId></ArticleIdList></Reference><Reference><Citation>Bodansky A et al. Autoantigen profiling reveals a shared post-COVID signature in fully recovered and long COVID patients. JCI Insight 8 (2023). 10.1172/jci.insight.169515</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.169515</ArticleId><ArticleId IdType="pmc">PMC10393220</ArticleId><ArticleId IdType="pubmed">37288661</ArticleId></ArticleIdList></Reference><Reference><Citation>Nunez-Castilla J et al. Potential Autoimmunity Resulting from Molecular Mimicry between SARS-CoV-2 Spike and Human Proteins. Viruses 14 (2022). 10.3390/v14071415</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v14071415</ArticleId><ArticleId IdType="pmc">PMC9318917</ArticleId><ArticleId IdType="pubmed">35891400</ArticleId></ArticleIdList></Reference><Reference><Citation>Muri J et al. Autoantibodies against chemokines post-SARS-CoV-2 infection correlate with disease course. Nat. Immunol 24, 604&#x2013;611 (2023). 10.1038/s41590-023-01445-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-023-01445-w</ArticleId><ArticleId IdType="pmc">PMC10063443</ArticleId><ArticleId IdType="pubmed">36879067</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen H-J et al. Transfer of IgG from Long COVID patients induces symptomology in mice. bioRxiv, 2024.2005.2030.596590 (2024). 10.1101/2024.05.30.596590</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2024.05.30.596590</ArticleId></ArticleIdList></Reference><Reference><Citation>Santos Guedes de Sa K et al. A causal link between autoantibodies and neurological symptoms in long COVID. medRxiv, 2024.2006.2018.24309100 (2024). 10.1101/2024.06.18.24309100</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2024.06.18.24309100</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee DSW, Rojas OL &amp; Gommerman JL B cell depletion therapies in autoimmune disease: advances and mechanistic insights. Nat. Rev. Drug Discov 20, 179&#x2013;199 (2021). 10.1038/s41573-020-00092-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41573-020-00092-2</ArticleId><ArticleId IdType="pmc">PMC7737718</ArticleId><ArticleId IdType="pubmed">33324003</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackensen A et al. Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus. Nat. Med 28, 2124&#x2013;2132 (2022). 10.1038/s41591-022-02017-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-02017-5</ArticleId><ArticleId IdType="pubmed">36109639</ArticleId></ArticleIdList></Reference><Reference><Citation>Kazatchkine MD &amp; Kaveri SV Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N. Engl. J. Med 345, 747&#x2013;755 (2001). 10.1056/NEJMra993360</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra993360</ArticleId><ArticleId IdType="pubmed">11547745</ArticleId></ArticleIdList></Reference><Reference><Citation>Shock A, Humphreys D &amp; Nimmerjahn F Dissecting the mechanism of action of intravenous immunoglobulin in human autoimmune disease: Lessons from therapeutic modalities targeting Fc&#x3b3; receptors. J. Allergy Clin. Immunol 146, 492&#x2013;500 (2020). 10.1016/j.jaci.2020.06.036</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaci.2020.06.036</ArticleId><ArticleId IdType="pubmed">32721416</ArticleId></ArticleIdList></Reference><Reference><Citation>Basta M et al. F(ab)&#x2019;2-mediated neutralization of C3a and C5a anaphylatoxins: a novel effector function of immunoglobulins. Nat. Med 9, 431&#x2013;438 (2003). 10.1038/nm836</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm836</ArticleId><ArticleId IdType="pubmed">12612546</ArticleId></ArticleIdList></Reference><Reference><Citation>Siedlar M et al. Preparations of intravenous immunoglobulins diminish the number and proinflammatory response of CD14+CD16++ monocytes in common variable immunodeficiency (CVID) patients. Clin. Immunol 139, 122&#x2013;132 (2011). 10.1016/j.clim.2011.01.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clim.2011.01.002</ArticleId><ArticleId IdType="pubmed">21300572</ArticleId></ArticleIdList></Reference><Reference><Citation>Trinath J et al. Intravenous immunoglobulin expands regulatory T cells via induction of cyclooxygenase-2&#x2013;dependent prostaglandin E2 in human dendritic cells. Blood 122, 1419&#x2013;1427 (2013). 10.1182/blood-2012-11-468264</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2012-11-468264</ArticleId><ArticleId IdType="pubmed">23847198</ArticleId></ArticleIdList></Reference><Reference><Citation>Bouck EG et al. COVID-19 and Sepsis Are Associated With Different Abnormalities in Plasma Procoagulant and Fibrinolytic Activity. Arterioscler. Thromb. Vasc. Biol 41, 401&#x2013;414 (2021). 10.1161/ATVBAHA.120.315338</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/ATVBAHA.120.315338</ArticleId><ArticleId IdType="pmc">PMC7942774</ArticleId><ArticleId IdType="pubmed">33196292</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang N, Li D, Wang X &amp; Sun Z Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J. Thromb. Haemost 18, 844&#x2013;847 (2020). 10.1111/jth.14768</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.14768</ArticleId><ArticleId IdType="pmc">PMC7166509</ArticleId><ArticleId IdType="pubmed">32073213</ArticleId></ArticleIdList></Reference><Reference><Citation>Merkler AE et al. Risk of Ischemic Stroke in Patients With Coronavirus Disease 2019 (COVID-19) vs Patients With Influenza. JAMA Neurol. 77, 1&#x2013;7 (2020). 10.1001/jamaneurol.2020.2730</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2020.2730</ArticleId><ArticleId IdType="pmc">PMC7333175</ArticleId><ArticleId IdType="pubmed">32614385</ArticleId></ArticleIdList></Reference><Reference><Citation>Fox SE et al. Pulmonary and cardiac pathology in African American patients with COVID-19: an autopsy series from New Orleans. Lancet Respir Med 8, 681&#x2013;686 (2020). 10.1016/S2213-2600(20)30243-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(20)30243-5</ArticleId><ArticleId IdType="pmc">PMC7255143</ArticleId><ArticleId IdType="pubmed">32473124</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryu JK et al. SARS-CoV-2 spike protein induces abnormal inflammatory blood clots neutralized by fibrin immunotherapy. bioRxiv (2021). 10.1101/2021.10.12.464152</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.10.12.464152</ArticleId></ArticleIdList></Reference><Reference><Citation>Merlini M et al. Fibrinogen Induces Microglia-Mediated Spine Elimination and Cognitive Impairment in an Alzheimer&#x2019;s Disease Model. Neuron 101, 1099&#x2013;1108.e1096 (2019). 10.1016/j.neuron.2019.01.014</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2019.01.014</ArticleId><ArticleId IdType="pmc">PMC6602536</ArticleId><ArticleId IdType="pubmed">30737131</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryu JK et al. Fibrin-targeting immunotherapy protects against neuroinflammation and neurodegeneration. Nat. Immunol 19, 1212&#x2013;1223 (2018). 10.1038/s41590-018-0232-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-018-0232-x</ArticleId><ArticleId IdType="pmc">PMC6317891</ArticleId><ArticleId IdType="pubmed">30323343</ArticleId></ArticleIdList></Reference><Reference><Citation>Taquet M et al. Acute blood biomarker profiles predict cognitive deficits 6 and 12 months after COVID-19 hospitalization. Nature Medicine (2023). 10.1038/s41591-023-02525-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-023-02525-y</ArticleId><ArticleId IdType="pmc">PMC10579097</ArticleId><ArticleId IdType="pubmed">37653345</ArticleId></ArticleIdList></Reference><Reference><Citation>Pretorius E et al. Persistent clotting protein pathology in Long COVID/Post-Acute Sequelae of COVID-19 (PASC) is accompanied by increased levels of antiplasmin. Cardiovasc. Diabetol 20, 172 (2021). 10.1186/s12933-021-01359-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12933-021-01359-7</ArticleId><ArticleId IdType="pmc">PMC8381139</ArticleId><ArticleId IdType="pubmed">34425843</ArticleId></ArticleIdList></Reference><Reference><Citation>Pretorius E et al. Prevalence of symptoms, comorbidities, fibrin amyloid microclots and platelet pathology in individuals with Long COVID/Post-Acute Sequelae of COVID-19 (PASC). Cardiovasc. Diabetol 21, 148 (2022). 10.1186/s12933-022-01579-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12933-022-01579-5</ArticleId><ArticleId IdType="pmc">PMC9356426</ArticleId><ArticleId IdType="pubmed">35933347</ArticleId></ArticleIdList></Reference><Reference><Citation>Pretorius E et al. Combined triple treatment of fibrin amyloid microclots and platelet pathology in individuals with Long COVID/Post-Acute Sequelae of COVID-19 (PASC) can resolve their persistent symptoms. Research Square (2021). 10.21203/rs.3.rs-1205453/v1</Citation><ArticleIdList><ArticleId IdType="doi">10.21203/rs.3.rs-1205453/v1</ArticleId></ArticleIdList></Reference><Reference><Citation>Cervia-Hasler C et al. Persistent complement dysregulation with signs of thromboinflammation in active Long Covid. Science 383, eadg7942 (2024). 10.1126/science.adg7942</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.adg7942</ArticleId><ArticleId IdType="pubmed">38236961</ArticleId></ArticleIdList></Reference><Reference><Citation>Weng Y, Yao J, Sparks S &amp; Wang KY Nattokinase: An Oral Antithrombotic Agent for the Prevention of Cardiovascular Disease. Int. J. Mol. Sci 18 (2017). 10.3390/ijms18030523</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms18030523</ArticleId><ArticleId IdType="pmc">PMC5372539</ArticleId><ArticleId IdType="pubmed">28264497</ArticleId></ArticleIdList></Reference><Reference><Citation>Kurosawa Y et al. A single-dose of oral nattokinase potentiates thrombolysis and anti-coagulation profiles. Sci. Rep 5, 11601 (2015). 10.1038/srep11601</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep11601</ArticleId><ArticleId IdType="pmc">PMC4479826</ArticleId><ArticleId IdType="pubmed">26109079</ArticleId></ArticleIdList></Reference><Reference><Citation>Damania B, Kenney SC &amp; Raab-Traub N Epstein-Barr virus: Biology and clinical disease. Cell 185, 3652&#x2013;3670 (2022). 10.1016/j.cell.2022.08.026</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2022.08.026</ArticleId><ArticleId IdType="pmc">PMC9529843</ArticleId><ArticleId IdType="pubmed">36113467</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso MJ et al. Chronic viral coinfections differentially affect the likelihood of developing long COVID. J. Clin. Invest 133 (2023). 10.1172/JCI163669</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI163669</ArticleId><ArticleId IdType="pmc">PMC9888380</ArticleId><ArticleId IdType="pubmed">36454631</ArticleId></ArticleIdList></Reference><Reference><Citation>Durstenfeld MS et al. Reduced exercise capacity, chronotropic incompetence, and early systemic inflammation in cardiopulmonary phenotype Long COVID. J. Infect. Dis (2023). 10.1093/infdis/jiad131</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiad131</ArticleId><ArticleId IdType="pmc">PMC10686699</ArticleId><ArticleId IdType="pubmed">37166076</ArticleId></ArticleIdList></Reference><Reference><Citation>Gold JE, Okyay RA, Licht WE &amp; Hurley DJ Investigation of Long COVID Prevalence and Its Relationship to Epstein-Barr Virus Reactivation. Pathogens 10 (2021). 10.3390/pathogens10060763</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pathogens10060763</ArticleId><ArticleId IdType="pmc">PMC8233978</ArticleId><ArticleId IdType="pubmed">34204243</ArticleId></ArticleIdList></Reference><Reference><Citation>Shikova E et al. Cytomegalovirus, Epstein-Barr virus, and human herpesvirus-6 infections in patients with myalgic &#x435;ncephalomyelitis/chronic fatigue syndrome. J. Med. Virol (2020). 10.1002/jmv.25744</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.25744</ArticleId><ArticleId IdType="pmc">PMC7687071</ArticleId><ArticleId IdType="pubmed">32129496</ArticleId></ArticleIdList></Reference><Reference><Citation>Jason LA, Corradi K, Torres-Harding S, Taylor RR &amp; King C Chronic fatigue syndrome: the need for subtypes. Neuropsychol. Rev 15, 29&#x2013;58 (2005). 10.1007/s11065-005-3588-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11065-005-3588-2</ArticleId><ArticleId IdType="pubmed">15929497</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L et al. Microbial infections in eight genomic subtypes of chronic fatigue syndrome/myalgic encephalomyelitis. J. Clin. Pathol 63, 156&#x2013;164 (2010). 10.1136/jcp.2009.072561</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jcp.2009.072561</ArticleId><ArticleId IdType="pmc">PMC2921262</ArticleId><ArticleId IdType="pubmed">19955554</ArticleId></ArticleIdList></Reference><Reference><Citation>Bjornevik K et al. Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis. Science 375, 296&#x2013;301 (2022). 10.1126/science.abj8222</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abj8222</ArticleId><ArticleId IdType="pubmed">35025605</ArticleId></ArticleIdList></Reference><Reference><Citation>Lanz TV et al. Clonally expanded B cells in multiple sclerosis bind EBV EBNA1 and GlialCAM. Nature 603, 321&#x2013;327 (2022). 10.1038/s41586-022-04432-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-04432-7</ArticleId><ArticleId IdType="pmc">PMC9382663</ArticleId><ArticleId IdType="pubmed">35073561</ArticleId></ArticleIdList></Reference><Reference><Citation>Yager JE et al. Valganciclovir for the Suppression of Epstein-Barr Virus Replication. J. Infect. Dis 216, 198&#x2013;202 (2017). 10.1093/infdis/jix263</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jix263</ArticleId><ArticleId IdType="pmc">PMC5854009</ArticleId><ArticleId IdType="pubmed">28838145</ArticleId></ArticleIdList></Reference><Reference><Citation>Kogelnik AM et al. Use of valganciclovir in patients with elevated antibody titers against Human Herpesvirus-6 (HHV-6) and Epstein-Barr Virus (EBV) who were experiencing central nervous system dysfunction including long-standing fatigue. J. Clin. Virol 37 Suppl 1, S33&#x2013;38 (2006). 10.1016/S1386-6532(06)70009-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1386-6532(06)70009-9</ArticleId><ArticleId IdType="pubmed">17276366</ArticleId></ArticleIdList></Reference><Reference><Citation>Montoya JG et al. Randomized clinical trial to evaluate the efficacy and safety of valganciclovir in a subset of patients with chronic fatigue syndrome. J. Med. Virol 85, 2101&#x2013;2109 (2013). 10.1002/jmv.23713</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.23713</ArticleId><ArticleId IdType="pubmed">23959519</ArticleId></ArticleIdList></Reference><Reference><Citation>Watt T et al. Response to valganciclovir in chronic fatigue syndrome patients with human herpesvirus 6 and Epstein-Barr virus IgG antibody titers. J. Med. Virol 84, 1967&#x2013;1974 (2012). 10.1002/jmv.23411</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.23411</ArticleId><ArticleId IdType="pubmed">23080504</ArticleId></ArticleIdList></Reference><Reference><Citation>Ancona G et al. Gut and airway microbiota dysbiosis and their role in COVID-19 and long-COVID. Front. Immunol 14, 1080043 (2023). 10.3389/fimmu.2023.1080043</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2023.1080043</ArticleId><ArticleId IdType="pmc">PMC10030519</ArticleId><ArticleId IdType="pubmed">36969243</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuo T et al. Alterations in Gut Microbiota of Patients With COVID-19 During Time of Hospitalization. Gastroenterology 159, 944&#x2013;955.e948 (2020). 10.1053/j.gastro.2020.05.048</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2020.05.048</ArticleId><ArticleId IdType="pmc">PMC7237927</ArticleId><ArticleId IdType="pubmed">32442562</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeoh YK et al. Gut microbiota composition reflects disease severity and dysfunctional immune responses in patients with COVID-19. Gut 70, 698&#x2013;706 (2021). 10.1136/gutjnl-2020-323020</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2020-323020</ArticleId><ArticleId IdType="pmc">PMC7804842</ArticleId><ArticleId IdType="pubmed">33431578</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Y, Zhang J, Zhang D, Ma W-L &amp; Wang X Linking the gut microbiota to persistent symptoms in survivors of COVID-19 after discharge. J. Microbiol 59, 941&#x2013;948 (2021). 10.1007/s12275-021-1206-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12275-021-1206-5</ArticleId><ArticleId IdType="pmc">PMC8356893</ArticleId><ArticleId IdType="pubmed">34382150</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Q et al. Gut microbiota dynamics in a prospective cohort of patients with post-acute COVID-19 syndrome. Gut 71, 544&#x2013;552 (2022). 10.1136/gutjnl-2021-325989</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2021-325989</ArticleId><ArticleId IdType="pubmed">35082169</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo C et al. Deficient butyrate-producing capacity in the gut microbiome is associated with bacterial network disturbances and fatigue symptoms in ME/CFS. Cell Host Microbe 31, 288&#x2013;304.e288 (2023). 10.1016/j.chom.2023.01.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2023.01.004</ArticleId><ArticleId IdType="pmc">PMC10183837</ArticleId><ArticleId IdType="pubmed">36758522</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiong R et al. Multi-&#x2019;omics of gut microbiome-host interactions in short- and long-term myalgic encephalomyelitis/chronic fatigue syndrome patients. Cell Host Microbe 31, 273&#x2013;287.e275 (2023). 10.1016/j.chom.2023.01.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2023.01.001</ArticleId><ArticleId IdType="pmc">PMC10353054</ArticleId><ArticleId IdType="pubmed">36758521</ArticleId></ArticleIdList></Reference><Reference><Citation>Giron LB et al. Plasma Markers of Disrupted Gut Permeability in Severe COVID-19 Patients. Front. Immunol 12, 686240 (2021). 10.3389/fimmu.2021.686240</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.686240</ArticleId><ArticleId IdType="pmc">PMC8219958</ArticleId><ArticleId IdType="pubmed">34177935</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoel H et al. Elevated markers of gut leakage and inflammasome activation in COVID-19 patients with cardiac involvement. J. Intern. Med 289, 523&#x2013;531 (2021). 10.1111/joim.13178</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/joim.13178</ArticleId><ArticleId IdType="pmc">PMC7536991</ArticleId><ArticleId IdType="pubmed">32976665</ArticleId></ArticleIdList></Reference><Reference><Citation>Yonker LM et al. Multisystem inflammatory syndrome in children is driven by zonulin-dependent loss of gut mucosal barrier. J. Clin. Invest 131 (2021). 10.1172/JCI149633</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI149633</ArticleId><ArticleId IdType="pmc">PMC8279585</ArticleId><ArticleId IdType="pubmed">34032635</ArticleId></ArticleIdList></Reference><Reference><Citation>Giron LB et al. Markers of fungal translocation are elevated during post-acute sequelae of SARS-CoV-2 and induce NF-&#x3ba;B signaling. JCI Insight 7 (2022). 10.1172/jci.insight.164813</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.164813</ArticleId><ArticleId IdType="pmc">PMC9462470</ArticleId><ArticleId IdType="pubmed">35727635</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalambokis GN &amp; Tsianos EV Rifaximin reduces endotoxemia and improves liver function and disease severity in patients with decompensated cirrhosis. Hepatology 55, 655&#x2013;656 (2012). 10.1002/hep.24751</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hep.24751</ArticleId><ArticleId IdType="pubmed">22030839</ArticleId></ArticleIdList></Reference><Reference><Citation>Lau RI et al. A synbiotic preparation (SIM01) for post-acute COVID-19 syndrome in Hong Kong (RECOVERY): a randomised, double-blind, placebo-controlled trial. The Lancet Infectious Diseases 24, 256&#x2013;265 (2024). 10.1016/S1473-3099(23)00685-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(23)00685-0</ArticleId><ArticleId IdType="pubmed">38071990</ArticleId></ArticleIdList></Reference><Reference><Citation>Guarnieri JW et al. Core mitochondrial genes are down-regulated during SARS-CoV-2 infection of rodent and human hosts. Sci. Transl. Med 15, eabq1533 (2023). 10.1126/scitranslmed.abq1533</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.abq1533</ArticleId><ArticleId IdType="pubmed">37556555</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso MJ et al. SARS-CoV-2 and Mitochondrial Proteins in Neural-Derived Exosomes of COVID-19. Ann. Neurol (2022). 10.1002/ana.26350</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.26350</ArticleId><ArticleId IdType="pmc">PMC9082480</ArticleId><ArticleId IdType="pubmed">35285072</ArticleId></ArticleIdList></Reference><Reference><Citation>de Boer E et al. Decreased Fatty Acid Oxidation and Altered Lactate Production during Exercise in Patients with Post-acute COVID-19 Syndrome. Am. J. Respir. Crit. Care Med 205, 126&#x2013;129 (2022). 10.1164/rccm.202108-1903LE</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/rccm.202108-1903LE</ArticleId><ArticleId IdType="pmc">PMC8865580</ArticleId><ArticleId IdType="pubmed">34665688</ArticleId></ArticleIdList></Reference><Reference><Citation>Shang C et al. SARS-CoV-2 Causes Mitochondrial Dysfunction and Mitophagy Impairment. Front. Microbiol 12, 780768 (2021). 10.3389/fmicb.2021.780768</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2021.780768</ArticleId><ArticleId IdType="pmc">PMC8770829</ArticleId><ArticleId IdType="pubmed">35069483</ArticleId></ArticleIdList></Reference><Reference><Citation>Guntur VP et al. Signatures of Mitochondrial Dysfunction and Impaired Fatty Acid Metabolism in Plasma of Patients with Post-Acute Sequelae of COVID-19 (PASC). Metabolites 12 (2022). 10.3390/metabo12111026</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/metabo12111026</ArticleId><ArticleId IdType="pmc">PMC9699059</ArticleId><ArticleId IdType="pubmed">36355108</ArticleId></ArticleIdList></Reference><Reference><Citation>Finnigan LEM et al. Efficacy and tolerability of an endogenous metabolic modulator (AXA1125) in fatigue-predominant long COVID: a single-centre, double-blind, randomised controlled phase 2a pilot study. EClinicalMedicine 59, 101946 (2023). 10.1016/j.eclinm.2023.101946</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2023.101946</ArticleId><ArticleId IdType="pmc">PMC10102537</ArticleId><ArticleId IdType="pubmed">37223439</ArticleId></ArticleIdList></Reference><Reference><Citation>Metwally AA, Mehta P, Johnson BS, Nagarjuna A &amp; Snyder MP COVID-19-Induced New-Onset Diabetes: Trends and Technologies. Diabetes 70, 2733&#x2013;2744 (2021). 10.2337/dbi21-0029</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/dbi21-0029</ArticleId><ArticleId IdType="pmc">PMC8660988</ArticleId><ArticleId IdType="pubmed">34686519</ArticleId></ArticleIdList></Reference><Reference><Citation>Michalakis K &amp; Ilias I COVID-19 and hyperglycemia/diabetes. World J. Diabetes 12, 642&#x2013;650 (2021). 10.4239/wjd.v12.i5.642</Citation><ArticleIdList><ArticleId IdType="doi">10.4239/wjd.v12.i5.642</ArticleId><ArticleId IdType="pmc">PMC8107977</ArticleId><ArticleId IdType="pubmed">33995851</ArticleId></ArticleIdList></Reference><Reference><Citation>Naveed Z et al. Association of COVID-19 Infection With Incident Diabetes. JAMA Netw Open 6, e238866 (2023). 10.1001/jamanetworkopen.2023.8866</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2023.8866</ArticleId><ArticleId IdType="pmc">PMC10114057</ArticleId><ArticleId IdType="pubmed">37071420</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie Y &amp; Al-Aly Z Risks and burdens of incident diabetes in long COVID: a cohort study. Lancet Diabetes Endocrinol 10, 311&#x2013;321 (2022). 10.1016/S2213-8587(22)00044-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-8587(22)00044-4</ArticleId><ArticleId IdType="pmc">PMC8937253</ArticleId><ArticleId IdType="pubmed">35325624</ArticleId></ArticleIdList></Reference><Reference><Citation>Faruqui S et al. Cholangiopathy After Severe COVID-19: Clinical Features and Prognostic Implications. Am. J. Gastroenterol 116, 1414&#x2013;1425 (2021). 10.14309/ajg.0000000000001264</Citation><ArticleIdList><ArticleId IdType="doi">10.14309/ajg.0000000000001264</ArticleId><ArticleId IdType="pubmed">33993134</ArticleId></ArticleIdList></Reference><Reference><Citation>Douaud G et al. SARS-CoV-2 is associated with changes in brain structure in UK Biobank. Nature (2022). 10.1038/s41586-022-04569-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-04569-5</ArticleId><ArticleId IdType="pmc">PMC9046077</ArticleId><ArticleId IdType="pubmed">35255491</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanson BA et al. Plasma Biomarkers of Neuropathogenesis in Hospitalized Patients With COVID-19 and Those With Postacute Sequelae of SARS-CoV-2 Infection. Neurology - Neuroimmunology Neuroinflammation 9 (2022). 10.1212/NXI.0000000000001151</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/NXI.0000000000001151</ArticleId><ArticleId IdType="pmc">PMC8901169</ArticleId><ArticleId IdType="pubmed">35256481</ArticleId></ArticleIdList></Reference><Reference><Citation>Frontera JA et al. Comparison of serum neurodegenerative biomarkers among hospitalized COVID-19 patients versus non-COVID subjects with normal cognition, mild cognitive impairment, or Alzheimer&#x2019;s dementia. Alzheimers. Dement 18, 899&#x2013;910 (2022). 10.1002/alz.12556</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/alz.12556</ArticleId><ArticleId IdType="pmc">PMC9011610</ArticleId><ArticleId IdType="pubmed">35023610</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanberg N et al. Neurochemical signs of astrocytic and neuronal injury in acute COVID-19 normalizes during long-term follow-up. EBioMedicine 70, 103512 (2021). 10.1016/j.ebiom.2021.103512</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2021.103512</ArticleId><ArticleId IdType="pmc">PMC8320425</ArticleId><ArticleId IdType="pubmed">34333238</ArticleId></ArticleIdList></Reference><Reference><Citation>Bozzetti S et al. Neurological symptoms and axonal damage in COVID-19 survivors: are there sequelae? Immunol. Res (2021). 10.1007/s12026-021-09220-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12026-021-09220-5</ArticleId><ArticleId IdType="pmc">PMC8346772</ArticleId><ArticleId IdType="pubmed">34363587</ArticleId></ArticleIdList></Reference><Reference><Citation>McGregor G et al. Clinical effectiveness of an online supervised group physical and mental health rehabilitation programme for adults with post-covid-19 condition (REGAIN study): multicentre randomised controlled trial. BMJ 384, e076506 (2024). 10.1136/bmj-2023-076506</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj-2023-076506</ArticleId><ArticleId IdType="pmc">PMC11134408</ArticleId><ArticleId IdType="pubmed">38325873</ArticleId></ArticleIdList></Reference><Reference><Citation>Fairbank R Long COVID exercise trials proposed by NIH raise alarm. Nature 616, 228&#x2013;229 (2023). 10.1038/d41586-023-00900-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/d41586-023-00900-w</ArticleId><ArticleId IdType="pubmed">37002390</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahamed J &amp; Laurence J Long COVID endotheliopathy: hypothesized mechanisms and potential therapeutic approaches. J. Clin. Invest 132 (2022). 10.1172/JCI161167</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI161167</ArticleId><ArticleId IdType="pmc">PMC9337829</ArticleId><ArticleId IdType="pubmed">35912863</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou M et al. Inflammatory Profiles and Clinical Features of Coronavirus 2019 Survivors 3 Months After Discharge in Wuhan, China. J. Infect. Dis 224, 1473&#x2013;1488 (2021). 10.1093/infdis/jiab181</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiab181</ArticleId><ArticleId IdType="pmc">PMC8083630</ArticleId><ArticleId IdType="pubmed">33822106</ArticleId></ArticleIdList></Reference><Reference><Citation>Fogarty H et al. Persistent endotheliopathy in the pathogenesis of long COVID syndrome. J. Thromb. Haemost 19, 2546&#x2013;2553 (2021). 10.1111/jth.15490</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.15490</ArticleId><ArticleId IdType="pmc">PMC8420256</ArticleId><ArticleId IdType="pubmed">34375505</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh I et al. Persistent Exertional Intolerance After COVID-19: Insights From Invasive Cardiopulmonary Exercise Testing. Chest 161, 54&#x2013;63 (2022). 10.1016/j.chest.2021.08.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chest.2021.08.010</ArticleId><ArticleId IdType="pmc">PMC8354807</ArticleId><ArticleId IdType="pubmed">34389297</ArticleId></ArticleIdList></Reference><Reference><Citation>Aj&#x10d;evi&#x107; M et al. Cerebral hypoperfusion in post-COVID-19 cognitively impaired subjects revealed by arterial spin labeling MRI. Sci. Rep 13, 5808 (2023). 10.1038/s41598-023-32275-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-023-32275-3</ArticleId><ArticleId IdType="pmc">PMC10086005</ArticleId><ArticleId IdType="pubmed">37037833</ArticleId></ArticleIdList></Reference><Reference><Citation>Modjtahedi BS, Do D, Luong TQ &amp; Shaw J Changes in the Incidence of Retinal Vascular Occlusions After COVID-19 Diagnosis. JAMA Ophthalmol. 140, 523&#x2013;527 (2022). 10.1001/jamaophthalmol.2022.0632</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaophthalmol.2022.0632</ArticleId><ArticleId IdType="pmc">PMC9011173</ArticleId><ArticleId IdType="pubmed">35420643</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolfrum S, Jensen KS &amp; Liao JK Endothelium-dependent effects of statins. Arterioscler. Thromb. Vasc. Biol 23, 729&#x2013;736 (2003). 10.1161/01.ATV.0000063385.12476.A7</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.ATV.0000063385.12476.A7</ArticleId><ArticleId IdType="pubmed">12615672</ArticleId></ArticleIdList></Reference><Reference><Citation>Daily statin reduces the risk of cardiovascular disease in people living with HIV, large NIH study finds. (2023).</Citation></Reference><Reference><Citation>Nafisa A et al. Endothelial function and dysfunction: Impact of metformin. Pharmacol. Ther 192, 150&#x2013;162 (2018). 10.1016/j.pharmthera.2018.07.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pharmthera.2018.07.007</ArticleId><ArticleId IdType="pubmed">30056057</ArticleId></ArticleIdList></Reference><Reference><Citation>Su JB Vascular endothelial dysfunction and pharmacological treatment. World J Cardiol 7, 719&#x2013;741 (2015). 10.4330/wjc.v7.i11.719</Citation><ArticleIdList><ArticleId IdType="doi">10.4330/wjc.v7.i11.719</ArticleId><ArticleId IdType="pmc">PMC4660468</ArticleId><ArticleId IdType="pubmed">26635921</ArticleId></ArticleIdList></Reference><Reference><Citation>Dallapellegrina L, Sciatti E &amp; Vizzardi E Ivabradine and endothelium: an update. Ther Adv Cardiovasc Dis 14, 1753944720934937 (2020). 10.1177/1753944720934937</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1753944720934937</ArticleId><ArticleId IdType="pmc">PMC7333483</ArticleId><ArticleId IdType="pubmed">32611276</ArticleId></ArticleIdList></Reference><Reference><Citation>Seeley M-C et al. High incidence of autonomic dysfunction and postural orthostatic tachycardia syndrome in patients with long-COVID: Implications for management and healthcare planning. Am. J. Med (2023). 10.1016/j.amjmed.2023.06.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjmed.2023.06.010</ArticleId><ArticleId IdType="pmc">PMC10307671</ArticleId><ArticleId IdType="pubmed">37391116</ArticleId></ArticleIdList></Reference><Reference><Citation>Monaghan A et al. Orthostatic Intolerance in Adults Reporting Long COVID Symptoms Was Not Associated With Postural Orthostatic Tachycardia Syndrome. Front. Physiol 13, 833650 (2022). 10.3389/fphys.2022.833650</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphys.2022.833650</ArticleId><ArticleId IdType="pmc">PMC8931464</ArticleId><ArticleId IdType="pubmed">35309052</ArticleId></ArticleIdList></Reference><Reference><Citation>Blitshteyn S &amp; Whitelaw S Postural orthostatic tachycardia syndrome (POTS) and other autonomic disorders after COVID-19 infection: a case series of 20 patients. Immunol. Res 69, 205&#x2013;211 (2021). 10.1007/s12026-021-09185-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12026-021-09185-5</ArticleId><ArticleId IdType="pmc">PMC8009458</ArticleId><ArticleId IdType="pubmed">33786700</ArticleId></ArticleIdList></Reference><Reference><Citation>Lau S-T et al. Tachycardia amongst subjects recovering from severe acute respiratory syndrome (SARS). Int. J. Cardiol 100, 167&#x2013;169 (2005). 10.1016/j.ijcard.2004.06.022</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijcard.2004.06.022</ArticleId><ArticleId IdType="pmc">PMC7132412</ArticleId><ArticleId IdType="pubmed">15820302</ArticleId></ArticleIdList></Reference><Reference><Citation>Faria D et al. Sympathetic Neural Overdrive, Aortic Stiffening, Endothelial Dysfunction, and Impaired Exercise Capacity in Severe COVID-19 Survivors: A Mid-Term Study of Cardiovascular Sequelae. Hypertension 80, 470&#x2013;481 (2023). 10.1161/HYPERTENSIONAHA.122.19958</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/HYPERTENSIONAHA.122.19958</ArticleId><ArticleId IdType="pmc">PMC9847692</ArticleId><ArticleId IdType="pubmed">36416143</ArticleId></ArticleIdList></Reference><Reference><Citation>Jimeno-Almaz&#xe1;n A, Pallar&#xe9;s JG, Buend&#xed;a-Romero &#xc1;, Mart&#xed;nez-Cava A &amp; Courel-Ib&#xe1;&#xf1;ez J Chronotropic Incompetence in Non-Hospitalized Patients with Post-COVID-19 Syndrome. J. Clin. Med. Res 10 (2021). 10.3390/jcm10225434</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm10225434</ArticleId><ArticleId IdType="pmc">PMC8617992</ArticleId><ArticleId IdType="pubmed">34830716</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdallah SJ et al. Symptoms, Pulmonary Function, and Functional Capacity Four Months after COVID-19. Ann. Am. Thorac. Soc 18, 1912&#x2013;1917 (2021). 10.1513/AnnalsATS.202012-1489RL</Citation><ArticleIdList><ArticleId IdType="doi">10.1513/AnnalsATS.202012-1489RL</ArticleId><ArticleId IdType="pmc">PMC8641826</ArticleId><ArticleId IdType="pubmed">33872135</ArticleId></ArticleIdList></Reference><Reference><Citation>Szekely Y et al. Cardiorespiratory Abnormalities in Patients Recovering from Coronavirus Disease 2019. J. Am. Soc. Echocardiogr 34, 1273&#x2013;1284.e1279 (2021). 10.1016/j.echo.2021.08.022</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.echo.2021.08.022</ArticleId><ArticleId IdType="pmc">PMC8425293</ArticleId><ArticleId IdType="pubmed">34508837</ArticleId></ArticleIdList></Reference><Reference><Citation>Margalit I et al. Risk Factors and Multidimensional Assessment of Long Coronavirus Disease Fatigue: A Nested Case-Control Study. Clin. Infect. Dis 75, 1688&#x2013;1697 (2022). 10.1093/cid/ciac283</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciac283</ArticleId><ArticleId IdType="pmc">PMC9383780</ArticleId><ArticleId IdType="pubmed">35403679</ArticleId></ArticleIdList></Reference><Reference><Citation>Xavier de Brito AS et al. Value of (123)I-MIBG SPECT for the assessment of dysautonomia in patients with long COVID. Int J Cardiol Heart Vasc 52, 101413 (2024). 10.1016/j.ijcha.2024.101413</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijcha.2024.101413</ArticleId><ArticleId IdType="pmc">PMC11060949</ArticleId><ArticleId IdType="pubmed">38694270</ArticleId></ArticleIdList></Reference><Reference><Citation>Mancini DM et al. Use of cardiopulmonary stress testing for patients with unexplained dyspnea post-Coronavirus disease. JACC Heart Fail. 9, 927&#x2013;937 (2021). 10.1016/j.jchf.2021.10.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jchf.2021.10.002</ArticleId><ArticleId IdType="pmc">PMC8629098</ArticleId><ArticleId IdType="pubmed">34857177</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown JT et al. Ongoing Exercise Intolerance Following COVID-19: A Magnetic Resonance-Augmented Cardiopulmonary Exercise Test Study. J. Am. Heart Assoc 11, e024207 (2022). 10.1161/JAHA.121.024207</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/JAHA.121.024207</ArticleId><ArticleId IdType="pmc">PMC9238618</ArticleId><ArticleId IdType="pubmed">35470679</ArticleId></ArticleIdList></Reference><Reference><Citation>Taub PR et al. Randomized Trial of Ivabradine in Patients With Hyperadrenergic Postural Orthostatic Tachycardia Syndrome. J. Am. Coll. Cardiol 77, 861&#x2013;871 (2021). 10.1016/j.jacc.2020.12.029</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2020.12.029</ArticleId><ArticleId IdType="pubmed">33602468</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdelnabi M et al. IVABRADINE EFFECTS ON COVID-19 INDUCED POSTURAL ORTHOSTATIC TACHYCARDIA SYNDROME. J. Am. Coll. Cardiol 81, 56 (2023). 10.1016/S0735-1097(23)00500-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0735-1097(23)00500-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Rhee SH, Pothoulakis C &amp; Mayer EA Principles and clinical implications of the brain-gut-enteric microbiota axis. Nat. Rev. Gastroenterol. Hepatol 6, 306&#x2013;314 (2009). 10.1038/nrgastro.2009.35</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrgastro.2009.35</ArticleId><ArticleId IdType="pmc">PMC3817714</ArticleId><ArticleId IdType="pubmed">19404271</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong et al. Serotonin reduction in post-acute sequelae of viral infection. Cell (2023), 10.1016/j.cell.2023.09.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2023.09.013</ArticleId><ArticleId IdType="pmc">PMC11227373</ArticleId><ArticleId IdType="pubmed">37848036</ArticleId></ArticleIdList></Reference><Reference><Citation>VanElzakker MB Chronic fatigue syndrome from vagus nerve infection: a psychoneuroimmunological hypothesis. Med. Hypotheses 81, 414&#x2013;423 (2013). 10.1016/j.mehy.2013.05.034</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mehy.2013.05.034</ArticleId><ArticleId IdType="pubmed">23790471</ArticleId></ArticleIdList></Reference><Reference><Citation>Bin N-R et al. An airway-to-brain sensory pathway mediates influenza-induced sickness. Nature 615, 660&#x2013;667 (2023). 10.1038/s41586-023-05796-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-023-05796-0</ArticleId><ArticleId IdType="pmc">PMC10033449</ArticleId><ArticleId IdType="pubmed">36890237</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong CK et al. Central glucagon-like peptide 1 receptor activation inhibits Toll-like receptor agonist-induced inflammation. Cell Metabolism 36, 130&#x2013;143.e135 (2024). 10.1016/j.cmet.2023.11.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmet.2023.11.009</ArticleId><ArticleId IdType="pubmed">38113888</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehdi SF et al. Glucagon-like peptide-1: a multi-faceted anti-inflammatory agent. Front Immunol 14, 1148209 (2023). 10.3389/fimmu.2023.1148209</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2023.1148209</ArticleId><ArticleId IdType="pmc">PMC10230051</ArticleId><ArticleId IdType="pubmed">37266425</ArticleId></ArticleIdList></Reference><Reference><Citation>Nahas Z et al. Two-year outcome of vagus nerve stimulation (VNS) for treatment of major depressive episodes. J. Clin. Psychiatry 66, 1097&#x2013;1104 (2005). 10.4088/jcp.v66n0902</Citation><ArticleIdList><ArticleId IdType="doi">10.4088/jcp.v66n0902</ArticleId><ArticleId IdType="pubmed">16187765</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng ZS, Simonian N, Wang J &amp; Rosario ER Transcutaneous vagus nerve stimulation improves Long COVID symptoms in a female cohort: a pilot study. Front Neurol 15, 1393371 (2024). 10.3389/fneur.2024.1393371</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2024.1393371</ArticleId><ArticleId IdType="pmc">PMC11097097</ArticleId><ArticleId IdType="pubmed">38756213</ArticleId></ArticleIdList></Reference><Reference><Citation>Fern&#xe1;ndez-Casta&#xf1;eda A et al. Mild respiratory COVID can cause multi-lineage neural cell and myelin dysregulation. Cell 0 (2022). 10.1016/j.cell.2022.06.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2022.06.008</ArticleId><ArticleId IdType="pmc">PMC9189143</ArticleId><ArticleId IdType="pubmed">35768006</ArticleId></ArticleIdList></Reference><Reference><Citation>Hellmuth J et al. Persistent COVID-19-associated neurocognitive symptoms in non-hospitalized patients. J. Neurovirol 27, 191&#x2013;195 (2021). 10.1007/s13365-021-00954-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13365-021-00954-4</ArticleId><ArticleId IdType="pmc">PMC7852463</ArticleId><ArticleId IdType="pubmed">33528824</ArticleId></ArticleIdList></Reference><Reference><Citation>Perez Giraldo GS et al. Neurologic Manifestations of Long COVID Differ Based on Acute COVID-19 Severity. Ann. Neurol 94, 146&#x2013;159 (2023). 10.1002/ana.26649</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.26649</ArticleId><ArticleId IdType="pmc">PMC10724021</ArticleId><ArticleId IdType="pubmed">36966460</ArticleId></ArticleIdList></Reference><Reference><Citation>Graham EL et al. Persistent neurologic symptoms and cognitive dysfunction in non-hospitalized Covid-19 &#x201c;long haulers&#x201d;. Ann Clin Transl Neurol 8, 1073&#x2013;1085 (2021). 10.1002/acn3.51350</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.51350</ArticleId><ArticleId IdType="pmc">PMC8108421</ArticleId><ArticleId IdType="pubmed">33755344</ArticleId></ArticleIdList></Reference><Reference><Citation>Ali ST et al. Evolution of neurologic symptoms in non-hospitalized COVID-19 &#x201c;long haulers&#x201d;. Ann. Clin. Transl. Neurol 9, 950&#x2013;961 (2022). 10.1002/acn3.51570</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.51570</ArticleId><ArticleId IdType="pmc">PMC9268866</ArticleId><ArticleId IdType="pubmed">35607826</ArticleId></ArticleIdList></Reference><Reference><Citation>Apple AC et al. Risk factors and abnormal cerebrospinal fluid associate with cognitive symptoms after mild COVID-19. Ann Clin Transl Neurol 9, 221&#x2013;226 (2022). 10.1002/acn3.51498</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.51498</ArticleId><ArticleId IdType="pmc">PMC8862406</ArticleId><ArticleId IdType="pubmed">35043593</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen M et al. Brain imaging and neuropsychological assessment of individuals recovered from a mild to moderate SARS-CoV-2 infection. Proc. Natl. Acad. Sci. U. S. A 120, e2217232120 (2023). 10.1073/pnas.2217232120</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2217232120</ArticleId><ArticleId IdType="pmc">PMC10235949</ArticleId><ArticleId IdType="pubmed">37220275</ArticleId></ArticleIdList></Reference><Reference><Citation>Hosp JA et al. Cerebral microstructural alterations in Post-COVID-condition are related to cognitive impairment, olfactory dysfunction and fatigue. Nat Commun 15, 4256 (2024). 10.1038/s41467-024-48651-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-024-48651-0</ArticleId><ArticleId IdType="pmc">PMC11102465</ArticleId><ArticleId IdType="pubmed">38762609</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Q &amp; Barres BA Microglia and macrophages in brain homeostasis and disease. Nat. Rev. Immunol 18, 225&#x2013;242 (2018). 10.1038/nri.2017.125</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri.2017.125</ArticleId><ArticleId IdType="pubmed">29151590</ArticleId></ArticleIdList></Reference><Reference><Citation>Monje M &amp; Iwasaki A The neurobiology of long COVID. Neuron 110, 3484&#x2013;3496 (2022). 10.1016/j.neuron.2022.10.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2022.10.006</ArticleId><ArticleId IdType="pmc">PMC9537254</ArticleId><ArticleId IdType="pubmed">36288726</ArticleId></ArticleIdList></Reference><Reference><Citation>Pilloni G et al. Tolerability and feasibility of at-home remotely supervised transcranial direct current stimulation (RS-tDCS): Single-center evidence from 6,779 sessions. Brain Stimul 15, 707&#x2013;716 (2022). 10.1016/j.brs.2022.04.014</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brs.2022.04.014</ArticleId><ArticleId IdType="pubmed">35470019</ArticleId></ArticleIdList></Reference><Reference><Citation>Muccio M et al. Cerebral metabolic rate of oxygen (CMRO(2)) changes measured with simultaneous tDCS-MRI in healthy adults. Brain Res 1796, 148097 (2022). 10.1016/j.brainres.2022.148097</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2022.148097</ArticleId><ArticleId IdType="pmc">PMC10335216</ArticleId><ArticleId IdType="pubmed">36150457</ArticleId></ArticleIdList></Reference><Reference><Citation>Brunoni AR &amp; Vanderhasselt MA Working memory improvement with non-invasive brain stimulation of the dorsolateral prefrontal cortex: a systematic review and meta-analysis. Brain Cogn 86, 1&#x2013;9 (2014). 10.1016/j.bandc.2014.01.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bandc.2014.01.008</ArticleId><ArticleId IdType="pubmed">24514153</ArticleId></ArticleIdList></Reference><Reference><Citation>The Lancet Infectious D. Where are the long COVID trials? Lancet Infect Dis 23, 879 (2023). 10.1016/S1473-3099(23)00440-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(23)00440-1</ArticleId><ArticleId IdType="pubmed">37507151</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalbandian A et al. Post-acute COVID-19 syndrome. Nat Med 27, 601&#x2013;615 (2021). 10.1038/s41591-021-01283-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01283-z</ArticleId><ArticleId IdType="pmc">PMC8893149</ArticleId><ArticleId IdType="pubmed">33753937</ArticleId></ArticleIdList></Reference><Reference><Citation>Scully EP, Haverfield J, Ursin RL, Tannenbaum C &amp; Klein SL Considering how biological sex impacts immune responses and COVID-19 outcomes. Nat. Rev. Immunol 20, 442&#x2013;447 (2020). 10.1038/s41577-020-0348-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-020-0348-8</ArticleId><ArticleId IdType="pmc">PMC7288618</ArticleId><ArticleId IdType="pubmed">32528136</ArticleId></ArticleIdList></Reference><Reference><Citation>Scully EP et al. Sex and Gender Differences in Testing, Hospital Admission, Clinical Presentation, and Drivers of Severe Outcomes From COVID-19. Open Forum Infect Dis 8, ofab448 (2021). 10.1093/ofid/ofab448</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ofid/ofab448</ArticleId><ArticleId IdType="pmc">PMC8465334</ArticleId><ArticleId IdType="pubmed">34584899</ArticleId></ArticleIdList></Reference><Reference><Citation>Silva J et al. Sex differences in symptomatology and immune profiles of Long COVID. medRxiv, 2024.2002.2029.24303568 (2024). 10.1101/2024.02.29.24303568</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2024.02.29.24303568</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein SL &amp; Flanagan KL Sex differences in immune responses. Nat Rev Immunol 16, 626&#x2013;638 (2016). 10.1038/nri.2016.90</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri.2016.90</ArticleId><ArticleId IdType="pubmed">27546235</ArticleId></ArticleIdList></Reference><Reference><Citation>Hagen S &amp; Altfeld M The X awakens: multifactorial ramifications of sex-specific differences in HIV-1 infection. J Virus Erad 2, 78&#x2013;81 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4965249</ArticleId><ArticleId IdType="pubmed">27482439</ArticleId></ArticleIdList></Reference><Reference><Citation>Rechtien A &amp; Altfeld M Sexual dimorphism in HIV-1 infection. Semin Immunopathol 41, 195&#x2013;202 (2019). 10.1007/s00281-018-0704-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00281-018-0704-y</ArticleId><ArticleId IdType="pubmed">30276445</ArticleId></ArticleIdList></Reference><Reference><Citation>Ziegler SM &amp; Altfeld M Human Immunodeficiency Virus 1 and Type I Interferons-Where Sex Makes a Difference. Front Immunol 8, 1224 (2017). 10.3389/fimmu.2017.01224</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2017.01224</ArticleId><ArticleId IdType="pmc">PMC5625005</ArticleId><ArticleId IdType="pubmed">29033943</ArticleId></ArticleIdList></Reference><Reference><Citation>Scully EP, Haverfield J, Ursin RL, Tannenbaum C &amp; Klein SL Considering how biological sex impacts immune responses and COVID-19 outcomes. Nat Rev Immunol 20, 442&#x2013;447 (2020). 10.1038/s41577-020-0348-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-020-0348-8</ArticleId><ArticleId IdType="pmc">PMC7288618</ArticleId><ArticleId IdType="pubmed">32528136</ArticleId></ArticleIdList></Reference><Reference><Citation>Scully EP Sex Differences in HIV Infection. Curr HIV/AIDS Rep 15, 136&#x2013;146 (2018). 10.1007/s11904-018-0383-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11904-018-0383-2</ArticleId><ArticleId IdType="pmc">PMC5882769</ArticleId><ArticleId IdType="pubmed">29504062</ArticleId></ArticleIdList></Reference><Reference><Citation>Altfeld M &amp; Scully EP Sex Differences in HIV Infection. Curr Top Microbiol Immunol 441, 61&#x2013;73 (2023). 10.1007/978-3-031-35139-6_3</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-3-031-35139-6_3</ArticleId><ArticleId IdType="pubmed">37695425</ArticleId></ArticleIdList></Reference><Reference><Citation>Giurgea LT et al. Sex Differences in Influenza: The Challenge Study Experience. The Journal of Infectious Diseases 225, 715&#x2013;722 (2021). 10.1093/infdis/jiab422</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiab422</ArticleId><ArticleId IdType="pmc">PMC8844587</ArticleId><ArticleId IdType="pubmed">34423369</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischinger S, Boudreau CM, Butler AL, Streeck H &amp; Alter G Sex differences in vaccine-induced humoral immunity. Semin Immunopathol 41, 239&#x2013;249 (2019). 10.1007/s00281-018-0726-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00281-018-0726-5</ArticleId><ArticleId IdType="pmc">PMC6373179</ArticleId><ArticleId IdType="pubmed">30547182</ArticleId></ArticleIdList></Reference><Reference><Citation>Furman D et al. Systems analysis of sex differences reveals an immunosuppressive role for testosterone in the response to influenza vaccination. Proceedings of the National Academy of Sciences 111, 869&#x2013;874 (2014). https://doi.org/doi:10.1073/pnas.1321060111</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1321060111</ArticleId><ArticleId IdType="pmc">PMC3896147</ArticleId><ArticleId IdType="pubmed">24367114</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein SL &amp; Flanagan KL Sex differences in immune responses. Nature Reviews Immunology 16, 626&#x2013;638 (2016). 10.1038/nri.2016.90</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri.2016.90</ArticleId><ArticleId IdType="pubmed">27546235</ArticleId></ArticleIdList></Reference><Reference><Citation>Ye Y et al. Sex-associated molecular differences for cancer immunotherapy. Nature Communications 11, 1779 (2020). 10.1038/s41467-020-15679-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-15679-x</ArticleId><ArticleId IdType="pmc">PMC7156379</ArticleId><ArticleId IdType="pubmed">32286310</ArticleId></ArticleIdList></Reference><Reference><Citation>Meier A et al. Sex differences in the Toll-like receptor-mediated response of plasmacytoid dendritic cells to HIV-1. Nat Med 15, 955&#x2013;959 (2009). 10.1038/nm.2004</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.2004</ArticleId><ArticleId IdType="pmc">PMC2821111</ArticleId><ArticleId IdType="pubmed">19597505</ArticleId></ArticleIdList></Reference><Reference><Citation>Ziegler SM et al. Human pDCs display sex-specific differences in type I interferon subtypes and interferon alpha/beta receptor expression. Eur J Immunol 47, 251&#x2013;256 (2017). 10.1002/eji.201646725</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/eji.201646725</ArticleId><ArticleId IdType="pubmed">27891600</ArticleId></ArticleIdList></Reference><Reference><Citation>Griesbeck M et al. Sex Differences in Plasmacytoid Dendritic Cell Levels of IRF5 Drive Higher IFN-alpha Production in Women. J Immunol 195, 5327&#x2013;5336 (2015). 10.4049/jimmunol.1501684</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1501684</ArticleId><ArticleId IdType="pmc">PMC4654231</ArticleId><ArticleId IdType="pubmed">26519527</ArticleId></ArticleIdList></Reference><Reference><Citation>Douin-Echinard V et al. Estrogen receptor alpha, but not beta, is required for optimal dendritic cell differentiation and [corrected] CD40-induced cytokine production. J Immunol 180, 3661&#x2013;3669 (2008). 10.4049/jimmunol.180.6.3661</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.180.6.3661</ArticleId><ArticleId IdType="pubmed">18322171</ArticleId></ArticleIdList></Reference><Reference><Citation>Laffont S et al. X-Chromosome complement and estrogen receptor signaling independently contribute to the enhanced TLR7-mediated IFN-alpha production of plasmacytoid dendritic cells from women. J Immunol 193, 5444&#x2013;5452 (2014). 10.4049/jimmunol.1303400</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1303400</ArticleId><ArticleId IdType="pubmed">25339659</ArticleId></ArticleIdList></Reference><Reference><Citation>Seillet C et al. The TLR-mediated response of plasmacytoid dendritic cells is positively regulated by estradiol in vivo through cell-intrinsic estrogen receptor alpha signaling. Blood 119, 454&#x2013;464 (2012). 10.1182/blood-2011-08-371831</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2011-08-371831</ArticleId><ArticleId IdType="pubmed">22096248</ArticleId></ArticleIdList></Reference><Reference><Citation>Souyris M et al. TLR7 escapes X chromosome inactivation in immune cells. Sci Immunol 3 (2018). 10.1126/sciimmunol.aap8855</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciimmunol.aap8855</ArticleId><ArticleId IdType="pubmed">29374079</ArticleId></ArticleIdList></Reference><Reference><Citation>Mousavi MJ, Mahmoudi M &amp; Ghotloo S Escape from X chromosome inactivation and female bias of autoimmune diseases. Mol Med 26, 127 (2020). 10.1186/s10020-020-00256-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s10020-020-00256-1</ArticleId><ArticleId IdType="pmc">PMC7727198</ArticleId><ArticleId IdType="pubmed">33297945</ArticleId></ArticleIdList></Reference><Reference><Citation>Webb K et al. Sex and Pubertal Differences in the Type 1 Interferon Pathway Associate With Both X Chromosome Number and Serum Sex Hormone Concentration. Front Immunol 9, 3167 (2018). 10.3389/fimmu.2018.03167</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2018.03167</ArticleId><ArticleId IdType="pmc">PMC6345344</ArticleId><ArticleId IdType="pubmed">30705679</ArticleId></ArticleIdList></Reference><Reference><Citation>Murira A &amp; Lamarre A Type-I Interferon Responses: From Friend to Foe in the Battle against Chronic Viral Infection. Front. Immunol 7, 609 (2016). 10.3389/fimmu.2016.00609</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2016.00609</ArticleId><ArticleId IdType="pmc">PMC5165262</ArticleId><ArticleId IdType="pubmed">28066419</ArticleId></ArticleIdList></Reference><Reference><Citation>Addo MM &amp; Altfeld M Sex-based differences in HIV type 1 pathogenesis. J Infect Dis 209 Suppl 3, S86&#x2013;92 (2014). 10.1093/infdis/jiu175</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiu175</ArticleId><ArticleId IdType="pmc">PMC4157516</ArticleId><ArticleId IdType="pubmed">24966195</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown GJ et al. TLR7 gain-of-function genetic variation causes human lupus. Nature 605, 349&#x2013;356 (2022). 10.1038/s41586-022-04642-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-04642-z</ArticleId><ArticleId IdType="pmc">PMC9095492</ArticleId><ArticleId IdType="pubmed">35477763</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrews JS, Boonyaratanakornkit JB, Krusinska E, Allen S &amp; Posada JA Assessment of the Impact of RNase in Patients With Severe Fatigue Related to Post-Acute Sequelae of SARS-CoV-2 Infection (PASC): A Randomized Phase 2 Trial of RSLV-132. Clinical Infectious Diseases (2024). 10.1093/cid/ciae205</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciae205</ArticleId><ArticleId IdType="pubmed">38728385</ArticleId></ArticleIdList></Reference><Reference><Citation>Tyndall A, Du W &amp; Breder CD The target product profile as a tool for regulatory communication: advantageous but underused. Nature Reviews Drug Discovery 16, 156&#x2013;156 (2017). 10.1038/nrd.2016.264</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrd.2016.264</ArticleId><ArticleId IdType="pmc">PMC5478920</ArticleId><ArticleId IdType="pubmed">28209989</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>